Pathology In Depth

Library › Blood donation, blood components and transfusion practice

Blood donation, blood components and transfusion practice

Last reviewed 2026-11-10 by a board-certified pathologist. 135 references.

Blood Donor Eligibility, Collection and Donor Infectious Disease Testing

Definition. Donor eligibility is the determination that a donor is qualified to donate blood and blood components. Suitability of the donation is the separate determination that the collected unit is acceptable for transfusion or further manufacture (21 CFR 630.3). In the United States, eligibility is based on the donor educational material, the medical history interview, a physical assessment on the day of donation and a review of the records of deferred donors. Suitability is based on the eligibility findings and on testing of every donation for relevant transfusion-transmitted infections (21 CFR 630.10; 21 CFR 630.30; 21 CFR 610.40). The federal rules for donors were rewritten by the FDA final rule of May 22, 2015, which created 21 CFR Part 630 (80 FR 29898), effective May 23, 2016.

Related page: The Rh Blood Group System: D, Weak and Partial D, RhCE Variants and Rh Typing Problems (donor RhD typing, weak D and the RhD-negative label) Related page: Blood Component Preparation, Storage, Shelf Life and Quality Control (processing of the collected unit) Related page: Blood Component Modification: Leukoreduction, Irradiation, Washing, Volume Reduction, Pathogen Reduction and CMV-Safe Components (leukoreduction, irradiation, pathogen reduction, CMV-safe components and bacterial control of platelets) Related page: Transfusion Reactions (septic reactions, TA-GVHD and hemovigilance)

Federal framework for donor eligibility and donation suitability

  • Responsible physician. A licensed physician designated by the collection establishment directs donor eligibility determinations, collection and immunization of donors. Examination of a donor with blood pressure or pulse outside the limits may not be delegated (21 CFR 630.3(i); 21 CFR 630.5).
  • Timing. Eligibility is determined on the day of donation and before collection. For components that cannot be stored for more than 24 hours, such as granulocytes, eligibility and the test sample may be obtained up to 2 calendar days before donation. Incomplete answers may be clarified within 24 hours of collection (21 CFR 630.10(c)).
  • Four elements of the determination. The deferred-donor records are consulted, the interval since the last donation is checked, the medical history is assessed and a physical assessment is performed (21 CFR 630.10(d)).
  • Donor education and acknowledgment. Before each donation the donor receives educational material on relevant transfusion-transmitted infections and acknowledges it (21 CFR 630.10(b)).
  • Paid and volunteer donors. Most allogeneic donations are from volunteers and are labeled "volunteer donor." Components from donors paid for the donation are labeled "paid donor" (Circular of Information 2024).
  • Suitability. A donation is suitable when the donor is not currently deferred, the eligibility findings are satisfactory and the required infectious disease tests are negative or nonreactive. An unsuitable allogeneic donation is not released, and the donor is deferred and notified (21 CFR 630.30).
  • Requalification. A deferred donor may become eligible again when a time-limited deferral has passed or when the donor meets an FDA-acceptable requalification method (21 CFR 630.35; 21 CFR 610.41(b)).

Relevant transfusion-transmitted infections

The regulation names ten relevant transfusion-transmitted infections: HIV-1 and HIV-2, hepatitis B virus (HBV), hepatitis C virus (HCV), HTLV-I and HTLV-II, Treponema pallidum, West Nile virus (WNV), Trypanosoma cruzi, Creutzfeldt-Jakob disease (CJD), variant CJD (vCJD) and Plasmodium species (21 CFR 630.3(h)(1)). Any other agent becomes a relevant transfusion-transmitted infection when a screening measure or FDA-licensed test exists and the agent has enough incidence or prevalence to affect the donor population, or may have been released accidentally or intentionally (21 CFR 630.3(h)(2)). FDA designated Zika virus a relevant transfusion-transmitted infection under this provision in 2016 and withdrew the designation on May 12, 2021, after which testing may be discontinued (FDA 2021).

Physical assessment of allogeneic and autologous donors

Requirements are set in 21 CFR 630.10(f); the autologous minimum is also in 21 CFR 630.20(a).

Criterion Requirement
Temperature Oral temperature not above 37.5 °C (99.5 °F)
Blood pressure Systolic 90–180 mm Hg; diastolic 50–100 mm Hg; outside these limits only after examination by the responsible physician
Pulse Regular, 50–100 beats/min; outside these limits only with a documented physician determination
Weight At least 50 kg (110 lb)
Hemoglobin, female allogeneic donor ≥12.5 g/dL or hematocrit ≥38%; 12.0–12.5 g/dL or hematocrit 36–38% only under an FDA-acceptable procedure that protects donor health
Hemoglobin, male allogeneic donor ≥13.0 g/dL or hematocrit ≥39%
Hemoglobin, autologous donor ≥11.0 g/dL or hematocrit ≥33%
Hemoglobin sample Fingerstick, venipuncture or an equivalent method; earlobe blood is not acceptable
Skin Phlebotomy site free of infection, inflammation and lesions; no punctures or scars indicating injected drugs
  • Previous rule (until May 23, 2016). All allogeneic donors needed hemoglobin of at least 12.5 g/dL or hematocrit of at least 38%. The 2015 rule raised the male minimum to 13.0 g/dL (39%) and allowed females 12.0–12.5 g/dL under an FDA-acceptable procedure. The autologous minimum of 11.0 g/dL was retained (80 FR 29898).
  • Donor age. Federal regulations set a minimum weight and no minimum age (21 CFR 630.10). Donors aged 16 and 17 years give a share of whole blood collections (Eder 2008).
  • Medical history. The medical history includes recent illness, medications, travel to areas endemic for a transfusion-transmitted infection, pregnancy at the time of donation or within the previous 6 weeks, receipt of a xenotransplantation product, and signs of intoxication or unreliable answers. A donor who states that the purpose of donating is to obtain an infectious disease test result is ineligible. Incarceration in a correctional institution for 72 or more consecutive hours in the past 12 months is listed as a risk factor for a relevant transfusion-transmitted infection (21 CFR 630.10(e)).

Donation intervals and collection limits

Limits are set in 21 CFR 630.15 for red cells and plasma after red cells, 21 CFR 640.21 for plateletpheresis and 21 CFR 640.65 for automated plasmapheresis.

Collection Limit
Whole blood or single-unit apheresis red cells No more than once in 8 weeks
Two-unit apheresis red cells No more than once in 16 weeks
Plateletpheresis, annual No more than 24 collections in a rolling 12-month period
Plateletpheresis yielding <6 × 10¹¹ platelets At least 2 calendar days to the next collection; no more than 2 collections in 7 calendar days
Plateletpheresis yielding ≥6 × 10¹¹ platelets At least 7 calendar days to the next collection
Plateletpheresis donor platelet count ≥150,000/µL before collection; intended post-donation count ≥100,000/µL; without a known count, fewer than 9.0 × 10¹¹ platelets collected
Automated plasmapheresis Collections not less than 2 days apart and not more than twice in 7 days
Plasma or platelets after whole blood or single-unit apheresis red cells 8-week deferral; collection allowed after 2 calendar days when the extracorporeal volume of the device is <100 mL
Plasma or platelets after two-unit red cell apheresis 16-week deferral
  • Exceptions to the red cell interval. A shorter interval is permitted for an autologous donation prescribed by the donor's physician, or for a dedicated donation for a recipient with documented exceptional medical need (21 CFR 630.15(a)(1)(ii)).
  • Source Plasma total protein. Total plasma protein is measured before each plasmapheresis and must be 6.0–9.0 g/dL (21 CFR 630.15(b)(4)).

Deferral for HIV risk: individual risk-based questions

FDA's guidance of May 2023 replaced deferrals based on male-to-male sex with individual risk-based questions asked of every donor (FDA 2023 HIV guidance).

Donor history Recommended deferral
Ever a positive HIV test, or ever taken medication to treat HIV Permanent
Oral pre-exposure or post-exposure prophylaxis (PrEP or PEP) 3 months from the last dose
Injectable PrEP or PEP 2 years from the last injection
New sexual partner, or more than one partner, in the past 3 months, together with anal sex in the past 3 months 3 months from the last sexual contact
Sex for money, drugs or other payment; nonprescription injection drug use 3 months from the last event
Sex with a person with a positive HIV test, or with a person who exchanged sex for payment or injected nonprescription drugs in the past 3 months 3 months from the last sexual contact
Allogeneic transfusion; percutaneous or mucosal exposure to another person's blood 3 months
Tattoo, ear or body piercing 3 months; no deferral for a tattoo applied by a state-regulated entity with sterile needles and non-reused ink, or a piercing with single-use equipment
Syphilis or gonorrhea, or treatment for either 3 months after completion of treatment
Hemophilia or a related factor deficiency treated with clotting factor concentrates Indefinite, for donor safety
  • Previous rule. FDA recommended indefinite deferral of men who had sex with men from September 1985, a 12-month deferral from December 2015 and a 3-month deferral from April 2020. The April 2020 guidance also shortened the deferrals for sex for payment and injection drug use from indefinite to 3 months, and the 12-month deferrals for transfusion, blood exposure, tattoo and piercing to 3 months. The May 2023 guidance kept these 3-month periods and removed the sex-specific questions (FDA 2023 HIV guidance).
  • Requalification. Donors previously deferred for male-to-male sex may return when they meet the new questions (FDA 2023 HIV guidance).

Deferrals for malaria, prion disease and babesiosis

Recommendations are from the FDA guidances on malaria (2022), CJD (2022) and babesiosis (2019).

Risk Current recommendation
Resident of a nonendemic country who traveled to a malaria-endemic area 3 months after departure, with or without chemoprophylaxis; platelets and plasma may be collected without deferral when pathogen reduced with a device effective against Plasmodium falciparum
Prior resident of a malaria-endemic country 3 years; pathogen reduction not an accepted alternative
Prior resident who returns to an endemic area after less than 3 consecutive years in nonendemic countries 3 years after the visit; pathogen reduction not an accepted alternative
Prior resident who returns to an endemic area after 3 or more consecutive years in nonendemic countries 3 months after return; platelets and plasma may be collected without deferral when pathogen reduced with a device effective against P. falciparum
History of malaria 3 years; pathogen reduction not an accepted alternative
Diagnosis of CJD, vCJD or another transmissible spongiform encephalopathy; blood relative with familial prion disease; cadaveric pituitary growth hormone Permanent
Cadaveric dura mater transplant Permanent; the only prion risk question recommended for the questionnaire
Reactive Babesia nucleic acid test (NAT) At least 2 years from the reactive donation
  • Malaria. The 12 US cases of transfusion-transmitted malaria between 2000 and 2021 involved donors who were former residents of endemic countries or had a prior malaria diagnosis. The December 2022 guidance kept the recommendations of April 2020 unchanged (FDA 2022 malaria guidance).
  • Pending malaria change. FDA licensed the first donor screening test for malaria, cobas Malaria (Roche), on March 19, 2024. It licensed a second, the Procleix Plasmodium Assay (Grifols), on March 16, 2026; it detects RNA of P. falciparum, P. knowlesi, P. malariae, P. ovale and P. vivax in individually tested donor samples on the Procleix Panther System. A draft guidance of January 2025 proposes selective NAT of donations from donors at risk. The draft is not for implementation, and the December 2022 deferrals remain current (FDA 2025 draft malaria guidance; FDA 2026 Procleix Plasmodium approval letter).
  • Variant CJD. The May 2022 guidance removed the geographic deferrals and the deferral for transfusion in the United Kingdom, France and Ireland. Donors deferred for these reasons may requalify (FDA 2022 CJD guidance).
  • Previous rule (until May 2022). Donors were deferred for time spent in the United Kingdom from 1980 to 1996, for time spent in France and Ireland from 1980 to 2001, and for transfusion in these three countries from 1980 to the present (FDA 2022 CJD guidance).
  • Basis of the vCJD change. Updated UK risk assessments and near-universal leukoreduction in the United States (Blood Component Modification: Leukoreduction, Irradiation, Washing, Volume Reduction, Pathogen Reduction and CMV-Safe Components) supported the change. In the United Kingdom, four vCJD infections were likely transmitted by transfusion, three of them by non-leukoreduced red cells transfused between 1996 and 1999. UK and US lookback studies of recipients of blood from donors with sporadic or familial CJD have found no transmitted case (FDA 2022 CJD guidance).
  • Babesiosis. Where neither Babesia NAT nor pathogen reduction is performed, donors are asked about a positive Babesia test and deferred indefinitely or for at least 2 years (FDA 2019 Babesia guidance).

Donor iron depletion and adverse reactions to donation

  • Iron deficiency. Iron deficiency affects 49% of men and 66% of women who donate frequently. Young donors, premenopausal females, frequent donors and donors with hemoglobin near the minimum are at risk. Frequent donors are males with 3 or more and females with 2 or more donations in 12 months (AABB Association Bulletin #17-02).
  • AABB recommendations. Collection establishments apply at least one strategy to all donors or to at-risk groups: iron supplementation without ferritin testing, a longer donation interval or fewer donations per year, or ferritin testing with action on low values. At least 18 mg of elemental iron daily for 60 days replaces the iron lost in one whole blood donation (AABB Association Bulletin #17-02, updated March 2026).
  • Vasovagal reactions. Complications followed 10.7% of whole blood donations by 16- and 17-year-olds and 2.8% of donations by donors aged 20 years or older. Young age, first-time donation and female sex were independent risk factors (Eder 2008).
  • Donor fatalities. The collecting facility reports a confirmed donation-related fatality to FDA as soon as possible and submits a written investigation within 7 days (21 CFR 606.170(b)).
  • Iron depletion and donation frequency. In the REDS-II RISE study of 2425 donors, 27% of returning female and 18% of returning male frequent donors had absent iron stores (ferritin <12 ng/mL) at the final visit. A shorter interdonation interval also predicted iron depletion, and iron supplements reduced its risk (Cable 2012).
  • Oral iron after donation. In a randomized trial of 215 donors, ferrous gluconate (37.5 mg elemental iron daily) shortened the mean time to recovery of 80% of the postdonation hemoglobin decrease from 158 to 32 days in donors with ferritin ≤26 ng/mL. Without iron, 67% of donors had not recovered iron stores by 168 days (Kiss 2015).
  • Donation interval. The INTERVAL trial randomized 45,263 whole blood donors in England to intervals of 8, 10 or 12 weeks (men) and 12, 14 or 16 weeks (women). Shorter intervals collected more blood over 2 years without a change in quality of life, physical activity or cognitive function. They caused more donation-related symptoms, lower hemoglobin and ferritin, and more deferrals for low hemoglobin (Di Angelantonio 2017).
  • Delayed and off-site reactions. Moderate or severe vasovagal reactions followed 41 of 10,000 whole blood and apheresis donations. Of these, 24% began more than 15 minutes after the procedure and 12% occurred off-site. Off-site reactions were more often associated with falls, head trauma and outside medical care. Low estimated blood volume was a major risk factor, and female donors had more delayed reactions (odds ratio 2.96) (Kamel 2010).
  • Citrate effects in apheresis donors. During plateletpheresis at a citrate infusion rate of 1.6 mg/kg per minute, ionized calcium fell 33% and ionized magnesium 39% below baseline. Donor symptoms became more severe as the citrate infusion rate increased (Bolan 2001).
  • Nerve injury. Neurologic needle injury followed 1 of every 6300 whole blood donations. Symptoms were numbness or tingling, excessive or radiating pain and, in 8 of 66 donors, loss of arm or hand strength. Of 56 donors followed up, 52 recovered fully, and recovery took more than 6 months in 2 (Newman 1996).
  • Rare serious reactions. In more than 22 million donations from six countries, the rate of vasovagal reactions with loss of consciousness and injury, or with off-site onset, was 1.53 per 100,000 donations. The most frequent localized rare reactions were cellulitis (0.31 per 100,000) and deep venous thrombosis (0.09 per 100,000) (Young 2021).

Autologous, directed and dedicated donations and therapeutic phlebotomy

Rules are from 21 CFR 630.15(a)(2), 630.20 and 610.40(c)–(d) and the Circular of Information (2024).

Donation type Rule
Autologous Prescribed by the donor's physician; hemoglobin ≥11.0 g/dL or hematocrit ≥33%; responsible physician documents that the donor's health permits collection
Autologous, testing Not required when drawn, stored and transfused in one facility that does not allow crossover; first donation in each 30-day period tested when shipped to a facility that does not allow crossover; all units tested when crossover is allowed
Autologous, labels "DONOR UNTESTED" when untested; "BIOHAZARD" and "FOR AUTOLOGOUS USE ONLY" when reactive; "DONOR TESTED WITHIN THE LAST 30 DAYS" for later untested units
Autologous crossover to the general inventory Donor and unit meet all allogeneic eligibility, suitability and testing requirements
Dedicated donation for one recipient Allowed for documented exceptional medical need when the physician documents no undue risk to donor or recipient; testing may be limited to the first donation in each 30-day period
Directed donation from a blood relative Cellular components are irradiated (Blood Component Modification: Leukoreduction, Irradiation, Washing, Volume Reduction, Pathogen Reduction and CMV-Safe Components)
Therapeutic phlebotomy Collection more often than every 8 weeks under prescription; label states the donor's disease
Therapeutic phlebotomy for hereditary hemochromatosis No disease label when the donor meets all eligibility criteria and the establishment performs these phlebotomies free of charge for all patients with the condition

Autologous units with reactive test results may be transfused to the donor with physician authorization (Circular of Information 2024).

Required infectious disease testing of each donation

Testing is performed by a laboratory registered with FDA and certified under CLIA, with FDA-licensed, approved or cleared screening tests used according to the manufacturer's instructions (21 CFR 610.40(b) and (f)). A reactive screening test is followed by a licensed supplemental test when one exists (21 CFR 610.40(e)). Requirements are from 21 CFR 610.40, the Circular of Information (2024) and the FDA guidances on T. cruzi (2017), babesiosis (2019), malaria (2022; 2025 draft) and HBV (2026).

Agent Required donor test Frequency and notes
HIV-1 and HIV-2 Anti-HIV-1/2; HIV-1 RNA by NAT Every donation
HCV Anti-HCV; HCV RNA by NAT Every donation
HBV HBV DNA by NAT and anti-HBc; HBsAg testing not necessary when both are performed and may be discontinued (establishments may continue it) Every donation; Source Plasma: HBsAg and HBV NAT, anti-HBc not recommended
HTLV-I and HTLV-II Anti-HTLV-I/II Every donation; not required for Source Plasma
T. pallidum Serologic test for syphilis Every donation; Source Plasma tested under 21 CFR 640.65; no further testing required after a reactive treponemal screen
WNV WNV RNA by NAT Every donation; not required for Source Plasma
T. cruzi Anti-T. cruzi One-time testing of each donor; not required for Source Plasma
Babesia Babesia NAT Year-round in Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, Virginia, Wisconsin and Washington, DC, unless platelets and plasma are pathogen reduced
Plasmodium Deferral questions; licensed NATs available since March 2024 (cobas Malaria) and March 2026 (Procleix Plasmodium) Selective testing proposed in draft guidance only
CJD and vCJD No licensed donor test Deferral questions only
Bacteria in platelets Culture or rapid test, or pathogen reduction Each platelet component (Blood Component Modification: Leukoreduction, Irradiation, Washing, Volume Reduction, Pathogen Reduction and CMV-Safe Components)
Cytomegalovirus Anti-CMV only for units labeled CMV-seronegative Optional additional test (Blood Component Modification: Leukoreduction, Irradiation, Washing, Volume Reduction, Pathogen Reduction and CMV-Safe Components)
  • Previous HBV rule (until November 2026). HBsAg was tested together with anti-HBc and HBV NAT on every donation, as listed in the June 2024 Circular (FDA 2026 HBV guidance; Circular of Information 2024).
  • Release before testing. Untested units may be released only in a documented medical emergency or for further manufacture approved by FDA. Testing is then completed and results are sent to the consignee promptly (21 CFR 610.40(g)). Granulocytes may be released for emergency use before infectious disease testing is complete because of their short shelf life (Circular of Information 2024).
  • Donor ABO, RhD and antibody testing. Each donation is typed for ABO by two tests and for RhD (The Rh Blood Group System: D, Weak and Partial D, RhCE Variants and Rh Typing Problems) and is tested for unexpected red cell antibodies (21 CFR 640.5(b) and (c); Circular of Information 2024).

Donor deferral and notification after reactive tests

  • Deferral. A donor with a reactive screening test for a relevant transfusion-transmitted infection is deferred from future donation (21 CFR 610.41(a)).
  • Single reactive anti-HBc or anti-HTLV. Deferral is not required after one reactive result. It is required when further testing is positive, when a second licensed screening test on the same donation is reactive or when the donor is reactive on more than one occasion (21 CFR 610.41(a)(1)).
  • Notification. Reasonable attempts are made to notify a deferred donor within 8 weeks. The notice gives the reason, the test results including further testing, the types of donation not to make and information on medical follow-up (21 CFR 630.40).
  • Bacterially contaminated platelets. When the responsible physician finds that the organism likely reflects a bacteremia endogenous to the donor, the donor is deferred and notified. This determination may not be delegated (21 CFR 606.145(d); 21 CFR 630.30(b)(3)).

Lookback and product retrieval

Requirements are set in 21 CFR 610.46 (HIV) and 21 CFR 610.47 (HCV).

Step HIV and HCV requirement
Record review Within 3 calendar days after a reactive screen or other reliable evidence of infection
Prior units quarantined In-date units collected 12 months or less before the donor's most recent nonreactive screen, or 12 months or less before a reactive NAT with nonreactive antibody screen, whichever is shorter
Consignee notified of further test results Within 45 calendar days after the reactive test
Recipient notification By the consignee when further testing is positive, through the recipient or the physician of record; reasonable attempts within 12 weeks of receiving the further-testing result
Status of the action Not a recall under 21 CFR 7.3
  • Malaria. When a donor should have been deferred for a history of malaria, distributed in-date cellular components are retrieved. The recipient's physician is encouraged to monitor the recipient for malaria for 3 months (FDA 2022 malaria guidance).
  • CJD. In-date components from a donor later diagnosed with CJD are retrieved and quarantined. Prior recipients are not traced, and pooled plasma for fractionation and plasma derivatives are not retrieved (FDA 2022 CJD guidance).

Residual risk of transfusion-transmitted infection

Agent Estimate Source
HIV, before donor testing in the 1980s About 1 in 2,500 units FDA 2023 HIV guidance
HIV, 2022 About 1 in 1.47 million transfusions FDA 2023 HIV guidance
HIV, HCV, HBV per donation, after the 2015 deferral change 1 in 1.6 million, 1 in 2.0 million and 1 in 1.0 million Steele 2021
Malaria <0.1 per million red cell transfusions FDA 2022 malaria guidance

Bacterial contamination of platelets is covered in Blood Component Modification: Leukoreduction, Irradiation, Washing, Volume Reduction, Pathogen Reduction and CMV-Safe Components.

Blood Component Preparation, Storage, Shelf Life and Quality Control

Definition. A blood component is a part of blood separated by physical or mechanical means (21 CFR 630.3(b)). Components are made from whole blood by centrifugation or sedimentation, or are collected directly by apheresis. Each component has a defined storage temperature and dating period, set in 21 CFR 610.53 unless the FDA-cleared instructions of the collection, processing and storage system specify otherwise. Content, indications and storage of each component are described in the Circular of Information, which FDA recognizes as an extension of the container label (Circular of Information 2024).

Related page: Blood Donor Eligibility, Collection and Donor Infectious Disease Testing (donor eligibility and donation testing) Related page: Blood Component Modification: Leukoreduction, Irradiation, Washing, Volume Reduction, Pathogen Reduction and CMV-Safe Components (leukoreduction, irradiation, washing, volume reduction and pathogen reduction) Related page: Blood Component Selection and Serologic Workup of Autoantibodies (ABO and RhD selection of each component, low-titer products and emergency release) Related page: Transfusion Reactions (septic and metabolic complications of stored components) Related page: Transfusion Indications, Massive Transfusion, Platelet Refractoriness and Patient Blood Management (indications, doses and expected increments of each component)

Anticoagulant-preservative and additive solutions

Whole blood is collected into 14 mL of anticoagulant-preservative solution per 100 mL of blood targeted for collection: 63 mL for a 450-mL collection and 70 mL for a 500-mL collection (Circular of Information 2024). Constituents and dating are from the Circular of Information (2024, Tables 1 and 2) and 21 CFR 610.53.

Solution Main constituents Red cell or whole blood shelf life at 1–6 °C
ACD-A Trisodium citrate, citric acid, dextrose; used for apheresis 21 days
CPD Citrate, phosphate, dextrose 21 days
CP2D CPD with twice the dextrose 21 days
CPDA-1 CPD with adenine 0.275 g/L 35 days
AS-1, AS-3, AS-5, AS-7 additive solutions Dextrose, adenine and salts (sodium chloride in AS-1, AS-3 and AS-5; phosphate and bicarbonate in AS-7); mannitol in AS-1, AS-5 and AS-7; citrate and phosphate in AS-3 42 days

Additive solution is added after nearly all plasma is removed: 100 mL for a 450-mL collection and 110 mL for a 500-mL collection. Red cells in additive solution have lower viscosity than red cells without it and flow more like whole blood (Circular of Information 2024).

Processing of whole blood into components

  • Collection volume. A whole blood donation contains 450 mL (±10%) or 500 mL (±10%) of blood (Circular of Information 2024).
  • Temperature before processing. Whole blood is stored at 1–6 °C immediately after collection unless it will be further processed or transported. Blood transported to the processing laboratory is cooled continuously toward 1–10 °C. Blood for components is held at the temperature specified for that component by the system instructions (21 CFR 640.4(h)).
  • Whole blood for platelets. Whole blood or plasma for platelets is held at 20–24 °C, and the platelet concentrate is separated within 4 hours or within the time in the system instructions (21 CFR 640.24(b)).
  • Platelet-rich plasma. Platelet-rich plasma is separated from red cells by centrifugation within 4 hours of phlebotomy. The centrifugation is shown to produce at least 250,000 platelets/µL (21 CFR 640.34(d)).
  • Platelet-rich plasma and buffy-coat methods. In the United States, whole-blood-derived components are prepared by the platelet-rich plasma method. Whole blood is centrifuged at relatively low speed (a soft spin) to yield red cells and platelet-rich plasma, and the platelet-rich plasma then undergoes a second, hard spin to yield platelet and plasma components (FDA 2026 buffy coat guidance). In the buffy-coat method the buffy layer is removed first and platelets are separated after a second centrifugation. Buffy-coat concentrates contained fewer white cells and red cells than platelet-rich plasma concentrates, with similar platelet yield and pH (Toora 2023). The buffy-coat method requires collection, processing and storage systems approved or cleared for it. FDA's final guidance of September 2026 sets development criteria for such systems, including whole blood holds of up to 24 hours before separation when the system's instructions support it (FDA 2026 buffy coat guidance). Canadian Blood Services replaced platelet-rich plasma concentrates with buffy-coat concentrates (Vassallo 2006).
  • Plasma. Plasma for Fresh Frozen Plasma is placed in a freezer within 8 hours of collection. Plasma Frozen Within 24 Hours After Phlebotomy is frozen within 24 hours. Plasma separated for Liquid Plasma is placed at 1–6 °C within 4 hours of filling the final container (21 CFR 640.34; Circular of Information 2024).

Red cell components

Content and dating are from the Circular of Information (2024) and 21 CFR 610.53.

Component Content Storage and dating
Whole Blood About 170 mL or more of plasma and about 5.5 × 10¹⁰ platelets; minimum donor hematocrit 38% for females (36% under the alternative standard) and 39% for males 1–6 °C; 21 days (CPD, CP2D, ACD) or 35 days (CPDA-1)
Red Blood Cells Hematocrit 65–80%; volume 225–350 mL; 160–275 mL of red cells (50–80 g hemoglobin); 20–100 mL of residual plasma 1–6 °C; 21 or 35 days by anticoagulant
Red Blood Cells, additive solution Hematocrit 55–65%; volume about 300–400 mL 1–6 °C; 42 days
Red Blood Cells Leukocytes Reduced <5.0 × 10⁶ leukocytes; ≥85% of original red cells As for the parent component
Red Blood Cells, AS, Leukocytes Reduced, O2/CO2 Reduced Stored in a system that limits oxygen and carbon dioxide 1–6 °C; up to 42 days
Apheresis Red Blood Cells About 60 g of hemoglobin per unit As for whole-blood-derived red cells
Frozen Red Blood Cells Glycerol added as cryoprotectant −65 °C or colder; 10 years, longer for rare units of exceptional need
Deglycerolized Red Blood Cells ≥80% of the original red cells; suspended in 0.9% sodium chloride Open system: 24 hours at 1–6 °C; closed system with additive solution: 14 days
Rejuvenated Red Blood Cells Inosine, phosphate and adenine restore 2,3-DPG and ATP; washed before infusion Transfused within 24 hours or frozen
  • Pediatric dose. The suggested pediatric dose is 10–15 mL/kg of red cells in additive solution, with an expected rise of 2 g/dL (Circular of Information 2024).
  • Frozen red cells. Frozen storage is used for red cells with unusual antigen phenotypes. Glycerol is removed by washing with progressively lower concentrations of sodium chloride. Inadequate deglycerolization causes intravascular hemolysis (Circular of Information 2024).

Red cell storage lesion and the age of transfused red cells

Refrigerated red cells undergo storage lesions that accumulate over the shelf life. Rapid loss of 2,3-diphosphoglycerate (2,3-DPG) and gradual loss of ATP occur during storage, and high-energy compounds and glutathione fall after about 2 weeks. ATP depletion leads to phosphatidylserine exposure, microparticle release, shape change from discocytes to spherocytes and reduced deformability. Hemolysis during storage is typically less than 0.8%. Removal of transfused red cells within 24 hours rises from over 6% after 1 week of storage to 11% after 6 weeks in healthy volunteers. ATP and 2,3-DPG recover 7–72 hours after transfusion (Yoshida 2019).

Licensure criteria for red cell storage systems. FDA criteria for in vivo 24-hour recovery require a mean of at least 75%, a standard deviation of 9% or less, and a lower one-sided 95% confidence limit of at least 70% for the proportion of successes. Hemolysis at the end of storage must be below 1% in at least 95% of units, with a one-sided 95% lower confidence limit (FDA 2023 De Novo decision summary BR220665).

Trial Population Comparison (mean or median storage) Primary outcome
ABLE (Lacroix 2015) 2,430 critically ill adults <8 days (6.1) vs standard issue (22.0) 90-day mortality 37.0% vs 35.3%; no difference
RECESS (Steiner 2015) 1,098 transfused cardiac surgery patients aged ≥12 years ≤10 days (median 7) vs ≥21 days (median 28) Change in organ dysfunction score; no difference
INFORM (Heddle 2016) 20,858 hospitalized patients with group A or O Freshest (13.0) vs oldest available (23.6) In-hospital mortality 9.1% vs 8.7%; no difference
TRANSFUSE (Cooper 2017) 4,919 critically ill adults Freshest (11.8) vs oldest available (22.4) 90-day mortality 24.8% vs 24.1%; no difference

None of the four trials showed a mortality or organ-dysfunction benefit from fresher red cells.

Platelet components

Content and storage are from the Circular of Information (2024) and 21 CFR 640.24 and 640.25.

Component Content and quality control Storage
Platelets (whole-blood-derived) ≥5.5 × 10¹⁰ platelets in 40–70 mL plasma; centrifugation validated to give this count in at least 75% of units tested 20–24 °C with continuous gentle agitation
Platelets Leukocytes Reduced (single unit) ≥5.5 × 10¹⁰ platelets; <8.3 × 10⁵ leukocytes As above
Pooled Platelets Leukocytes Reduced <5 × 10⁶ leukocytes in the pool Poststorage pool prepared in an open system expires 4 hours after pooling (FDA 2020 bacterial guidance)
Apheresis Platelets ≥3.0 × 10¹¹ platelets, equivalent to about 6 whole-blood-derived units; collected in ACD-A As above
Apheresis Platelets Leukocytes Reduced ≥3.0 × 10¹¹ platelets; <5.0 × 10⁶ leukocytes; ≥85% recovery when filtered after collection As above
Apheresis Platelets, platelet additive solution added ≥3.0 × 10¹¹ platelets in plasma and PAS-C or PAS-F; plasma proteins diluted in proportion As above
  • pH quality control. The volume of resuspending plasma maintains pH at no less than 6.2 through the storage period. Each month, four units from different donors are tested at the end of storage for platelet count, pH of at least 6.2 and actual plasma volume (21 CFR 640.24(d); 21 CFR 640.25(b)).
  • Previous rule (before February 19, 2008). The end-of-storage pH minimum was 6.0 (72 FR 45883; 73 FR 7464).
  • Dating. The regulatory dating for platelets at 20–24 °C is 5 days from collection unless the storage system instructions allow longer (21 CFR 610.53). Conventional platelets carry a 5-, 6- or 7-day expiration depending on the bacterial risk control strategy (Circular of Information 2024). The strategies are described in Blood Component Modification: Leukoreduction, Irradiation, Washing, Volume Reduction, Pathogen Reduction and CMV-Safe Components.

Cold-stored platelets

  • Current rule. Apheresis platelets in 100% plasma or an FDA-approved platelet additive solution may be stored at 1–6 °C for up to 14 days from collection. They are intended for active bleeding when conventional platelets are not available or their use is not practical (FDA 2023 cold-stored platelet guidance).
  • Manufacture. Platelets not pathogen reduced are placed at 1–6 °C within 4 hours of the end of collection. Agitation is optional. Shipping is at 1–10 °C, and units placed at room temperature are not returned to cold inventory or relabeled as room-temperature platelets (FDA 2023 cold-stored platelet guidance).
  • Quality control. Validation shows with 95% confidence that more than 75% of units keep pH of at least 6.2 at the end of storage, for example 11 units tested with no failures. End-of-storage platelet count and plasma volume testing are waived. Cold storage counts as an adequate bacterial risk control method (FDA 2023 cold-stored platelet guidance).
  • Biology. Cold-stored platelets show greater aggregation responses and clot strength in vitro and impaired in vivo recovery and circulation in older studies of whole-blood-derived cold-stored platelets. They may form aggregates during storage (FDA 2023 cold-stored platelet guidance).
  • Previous rule (before June 2023). Cold-stored platelets were used under a variance that allowed 3-day storage (FDA 2023 cold-stored platelet guidance).
  • Clinical data. In a phase 2 trial in severely injured patients, early transfusion of one apheresis unit stored cold for up to 14 days was feasible. Mortality at 24 hours was 5.9% versus 10.2% with standard care, a nonsignificant difference, with no excess thrombosis (Sperry 2024).

Plasma components

Preparation, dating and factor content are from the Circular of Information (2024), 21 CFR 640.34 and 21 CFR 610.53.

Component Preparation Storage and dating Labile factors
Fresh Frozen Plasma (FFP) Frozen at −18 °C or colder within 8 hours or the system's time frame; 200–250 mL, apheresis units up to 400–600 mL −18 °C or colder; 1 year Normal factors V and VIII
Plasma Frozen Within 24 Hours After Phlebotomy (PF24) Whole blood plasma separated and frozen within 24 hours; apheresis plasma refrigerated within 8 hours and frozen within 24 hours −18 °C or colder; 1 year Factor VIII and protein C reduced; factor V variable
PF24 held at room temperature up to 24 hours (PF24RT24) Held at room temperature up to 24 hours, then frozen −18 °C or colder; 1 year Factors V and VIII and protein S reduced
Plasma Cryoprecipitate Reduced Supernatant after removal of cryoprecipitate, refrozen within 24 hours of thawing −18 °C or colder; 1 year Reduced in fibrinogen, factor VIII, factor XIII, von Willebrand factor (vWF) and cryoglobulin; high-molecular-weight vWF multimers markedly decreased; factors II, V, VII, IX, X, XI and ADAMTS13 retained
Thawed Plasma From FFP, PF24 or PF24RT24 collected in a functionally closed system 1–6 °C for 4 days after the first 24 hours after thawing Stable factors similar to FFP; others variably reduced
Thawed Plasma Cryoprecipitate Reduced From Plasma Cryoprecipitate Reduced 1–6 °C for 4 days after the first 24 hours after thawing As for the parent component
Liquid Plasma Separated from whole blood and never frozen 1–6 °C; 5 days after the whole blood expiration date Not fully characterized; contains viable lymphocytes
  • Thawing. FFP is thawed at 30–37 °C in a water bath, in a protective overwrap, or in an FDA-cleared device (Circular of Information 2024).
  • After thawing. FFP, PF24 and PF24RT24 are transfused immediately or stored at 1–6 °C. After 24 hours they are discarded or, when collected in a functionally closed system, relabeled as Thawed Plasma (Circular of Information 2024).
  • Factor levels. At thawing, mean factor VIII was 81 IU/dL in FFP and 66 IU/dL in PF24. After 120 hours at 1–6 °C, factor V fell by 21% in FFP and 31% in PF24 and factor VIII by 47% and 28%. Fibrinogen and factor II changed little (Circular of Information 2024, Table 4).
  • Restrictions on use. PF24 and PF24RT24 are not indicated for deficiencies of labile factors. Plasma Cryoprecipitate Reduced is used in plasma exchange for thrombotic thrombocytopenic purpura. Liquid Plasma is indicated for initial treatment in massive transfusion for life-threatening trauma or hemorrhage (Circular of Information 2024).
  • Other dating. Plasma not labeled as one of these components is stored at −18 °C or colder for 5 years (21 CFR 610.53).

Cryoprecipitated AHF and pathogen-reduced cryoprecipitated fibrinogen complex

Features are from the Circular of Information (2024) and 21 CFR 610.53.

Feature Cryoprecipitated AHF Pathogen Reduced Cryoprecipitated Fibrinogen Complex (PRCFC)
Preparation Frozen plasma thawed at 1–6 °C; precipitate refrozen at −18 °C or colder within 1 hour of removal from the centrifuge Pathogen-reduced plasma thawed at 1–6 °C; precipitate frozen at −18 °C or colder
Content ≥80 IU factor VIII and ≥150 mg fibrinogen per unit in 5–20 mL; factor XIII and vWF Fibrinogen, factor XIII and vWF; about 740 ± 166 mg fibrinogen immediately after thawing in a unit made from 2 plasma units
Frozen dating 1 year from collection of the oldest source unit Per the device instructions
After thawing Room temperature; within 6 hours as a single unit or pool made with a sterile connecting device; within 4 hours after an open entry 5 days after thawing; within 4 hours if pooled or aliquoted without a sterile connecting device
  • Quality control. At least four representative units are tested each month for factor VIII. The average must be at least 80 IU per container, and results are received within 30 days of preparation (21 CFR 640.54(b); 21 CFR 640.56).
  • Thawing. Units are thawed at 30–37 °C for up to 15 minutes and are not refrozen (Circular of Information 2024).

Apheresis granulocytes

  • Content. Each unit usually contains more than 1.0 × 10¹⁰ granulocytes, platelets and 20–50 mL of red cells in a final volume of 200–300 mL. Donors may receive granulocyte colony-stimulating factor or corticosteroids, and a red cell sedimenting agent such as hydroxyethyl starch is used during collection (Circular of Information 2024).
  • Storage. Units are transfused as soon as possible and within 24 hours of collection. If stored, they are kept at 20–24 °C without agitation (Circular of Information 2024).
  • Processing. Units are irradiated (Blood Component Modification: Leukoreduction, Irradiation, Washing, Volume Reduction, Pathogen Reduction and CMV-Safe Components) and are not given through leukocyte reduction or depth-type microaggregate filters (Circular of Information 2024).
  • Indication. Granulocytes are used for bacterial or fungal infection unresponsive to antimicrobials in neutropenia below 0.5 × 10⁹/L with expected marrow recovery, and for hereditary neutrophil function defects. Support continues at least daily until infection resolves or the neutrophil count reaches 0.5 × 10⁹/L (Circular of Information 2024).

Low-titer group O whole blood

  • Product. Whole blood is stored at 1–6 °C with a shelf life set by the anticoagulant. Leukoreduced whole blood contains <5.0 × 10⁶ leukocytes and may be made with a platelet-sparing filter (Circular of Information 2024; 21 CFR 610.53).
  • Use. In a 2021 survey, 43 of 103 (42%) US adult level 1 trauma centers used low-titer group O whole blood. Unlimited units per patient were allowed at only 5 of the 43 (12%) (Yazer 2021).
  • Collection practice. In a survey of 10 large US collectors, estimated by the respondents to supply about 80% of US blood, all collected low-titer group O whole blood from male donors and 7 of 10 also from never-pregnant females. The most common titer defining "low" was <200 (6 of 10), and the most common method was collection in CPD with a platelet-sparing leukoreduction filter (5 of 10) (Yazer 2026). Titer policy and selection are covered in Blood Component Selection and Serologic Workup of Autoantibodies.

Labeling of blood components and ISBT 128

  • Label content. The label states the proper name and attributes, the collection method (whole blood or apheresis), the storage temperature, the anticoagulant, the volume or number of pooled units, the collecting and processing facility with registration and license numbers, the expiration date, the donation identification number, the donor category, the ABO group and RhD type, special handling and any sedimenting agent (Circular of Information 2024).
  • Expiration time. Products with a dating period of 72 hours or less carry an expiration hour. Without a stated time, the product expires at midnight (Circular of Information 2024).
  • ISBT 128 names. Components in the Circular are named with ISBT 128 product names (Circular of Information 2024).
  • ISBT 128 structure. ISBT 128 is the global standard for identification, labeling and information transfer for blood, cell, tissue and organ products. The donation identification number has a five-character facility identification number, a two-character year and a six-character serial number, and it is unique worldwide for 100 years. Product codes have a five-character product description code, a one-character donation type and a two-character division code (Distler 2010).

Storage and shipping temperatures of blood components

Temperatures are set in 21 CFR 600.15, 610.53 and 640, and in the 2023 FDA cold-stored platelet guidance; granulocyte storage follows the Circular of Information (2024).

Component Storage Shipping
Whole Blood and red cells 1–6 °C 1–10 °C
Frozen Red Blood Cells −65 °C or colder −65 °C or colder
Platelets, conventional 20–24 °C with agitation As close as possible to 20–24 °C
Platelets, cold-stored 1–6 °C 1–10 °C
FFP, Plasma and Cryoprecipitated AHF −18 °C or colder −18 °C or colder
Liquid Plasma 1–6 °C 1–10 °C
Granulocytes 20–24 °C without agitation, ≤24 hours Not specified
  • Opened containers. A container entered in a way that breaks the closed system expires 4 hours after entry at 20–24 °C or 24 hours after entry at 1–6 °C (Circular of Information 2024).

Blood inventory management

A provincial benchmarking program in Ontario reduced the annual red cell outdating rate from 2.82% to 1.02% in 2011. Dynamic targets, information sharing and a data system to track disposition were its main elements (Barty 2015).

blood component storage and shipping temperature lookup

Blood Component Modification: Leukoreduction, Irradiation, Washing, Volume Reduction, Pathogen Reduction and CMV-Safe Components

Definition. Further processing changes a collected component to reduce a specific hazard to the recipient. The processes in current US use are pathogen reduction, leukocyte reduction, irradiation, washing and volume reduction, and one component may undergo more than one of them. Identification of CMV-seronegative blood is an additional test performed on the donation (Circular of Information 2024). Control of bacterial contamination of platelets is a federal requirement for collection establishments and transfusion services (21 CFR 606.145).

Related page: Transfusion Reactions (clinical features of TA-GVHD, febrile, allergic, hypotensive and septic reactions) Related page: Blood Component Selection and Serologic Workup of Autoantibodies (washing and volume reduction for ABO-incompatible plasma) Related page: Blood Component Preparation, Storage, Shelf Life and Quality Control (unmodified components, storage and dating) Related page: Blood Donor Eligibility, Collection and Donor Infectious Disease Testing (donor testing and the malaria and Babesia alternatives that use pathogen reduction)

Comparison of component modifications

Entries are from the Circular of Information (2024), with pathogen reduction dating from the 2020 FDA bacterial guidance.

Modification Removes or inactivates Main purpose Does not achieve Effect on dating
Leukoreduction White cells, to <5.0 × 10⁶ per unit Fewer recurrent febrile reactions, less HLA alloimmunization, lower CMV transmission Prevention of TA-GVHD None
Irradiation Proliferative capacity of T lymphocytes Prevention of TA-GVHD Removal of white cells or plasma Red cells: 28 days after irradiation if shorter; platelets and Liquid Plasma unchanged
Washing Plasma proteins, antibodies, glycerol and additives Prevention of severe allergic reactions; removal of incompatible antibody Leukoreduction 24 hours at 1–6 °C or 4 hours at 20–24 °C
Volume reduction Part of the plasma and storage medium Less volume; fewer incompatible antibodies Replacement of washing or of small aliquots 24 hours at 1–6 °C or 4 hours at 20–24 °C
Pathogen reduction (amotosalen and UVA light) Many pathogens and residual lymphocytes Fewer transfusion-transmitted infections, including sepsis; alternative to irradiation for platelets Inactivation of every pathogen Platelets: 5 days per device instructions
CMV-seronegative selection Units from CMV-seropositive donors Lower CMV transmission to at-risk recipients Removal of white cells None

Leukoreduction

Residual white cell limits and quality control of leukoreduced components

Limits are from the Circular of Information (2024) and the 2012 FDA leukocyte reduction guidance.

Component Residual white cells Recovery
Whole blood and red cells, leukocytes reduced <5.0 × 10⁶ per unit ≥85% of original red cells
Apheresis platelets, leukocytes reduced <5.0 × 10⁶ per unit ≥85% of the prefiltration platelet content when filtered after collection
Whole-blood-derived platelets, single unit <8.3 × 10⁵ per unit ≥85% of platelet yield; >5.5 × 10¹⁰ platelets in 75% of units
Pooled whole-blood-derived platelets <5.0 × 10⁶ per pool Per device
Plasma components <5.0 × 10⁶ per unit Not applicable
  • Statistical standard. Validation and quality control use a plan that shows with 95% confidence that more than 95% of components meet the residual count. Residual white cells are counted within 48 hours of collection or as the manufacturer directs (FDA 2012 leukocyte reduction guidance).
  • Lower-count label. A component other than whole-blood-derived platelets with a directly counted residual of <1.0 × 10⁶ may carry a supplemental tie-tag stating that count (FDA 2012 leukocyte reduction guidance).
  • European limit. The Council of Europe Guide (17th edition) and the UK Blood Safety and Quality Regulations 2005 set <1 × 10⁶ leukocytes per unit. The UK Red Book (8th edition) specifies that more than 95% of components contain <5 × 10⁶ and more than 90% contain <1 × 10⁶. UK services monitor at 1 × 10⁶ and discard above 5 × 10⁶ (JPAC 2015).
  • Timing. Leukoreduction is performed during collection, soon after collection (prestorage), after storage in the laboratory or at the bedside. Laboratory methods undergo quality control; bedside filtration does not (Circular of Information 2024).
  • Bedside filtration and hypotension. Bedside leukoreduction filters are associated with sudden severe hypotension, particularly in recipients taking angiotensin-converting enzyme inhibitors (Transfusion Reactions). FDA considers prestorage leukoreduction generally preferable (FDA 2012 leukocyte reduction guidance).
  • Extent of use. About 97% of US red cell and platelet units are leukoreduced (FDA 2022 CJD guidance).

Established and potential benefits of leukoreduction

Effects are from the 2012 FDA leukocyte reduction guidance and the Circular of Information (2024).

Category Effect
Established Fewer recurrent febrile nonhemolytic reactions (two or more previous febrile reactions)
Established Less alloimmunization to leukocyte antigens and HLA
Established Lower transmission of CMV to patients at increased risk
Potential (unproven) Less transfusion-associated immunomodulation, bacterial overgrowth, viral reactivation, reperfusion injury after cardiopulmonary bypass, storage lesions, and transmission of Leishmania and vCJD

Febrile reactions follow less than 1% of leukoreduced red cell transfusions and about 5% of leukoreduced apheresis platelet transfusions (Circular of Information 2024).

  • Universal leukoreduction in adults. A retrospective before-and-after study of 14,786 adults transfused after cardiac surgery, hip fracture repair, surgery requiring intensive care or multiple trauma assessed the Canadian universal prestorage leukoreduction program. After its introduction, the adjusted odds of in-hospital death (odds ratio 0.87), posttransfusion fever (0.86) and antibiotic use (0.90) were lower. Serious nosocomial infections did not decrease (odds ratio 0.97) (Hébert 2003).
  • Universal leukoreduction in premature infants. In a retrospective before-and-after study of 515 transfused infants weighing <1250 g in 3 Canadian NICUs, universal leukoreduction was not associated with lower NICU mortality or bacteremia. It was associated with lower adjusted odds of bronchopulmonary dysplasia (0.42), retinopathy of prematurity (0.56) and necrotizing enterocolitis (0.39) (Fergusson 2003).

Irradiation

Irradiation dose and irradiator control

  • Dose. Gamma or x-ray irradiation delivers 2,500 cGy (25 Gy) to the central portion of the container, with a minimum of 1,500 cGy (15 Gy) to any part of the component (Circular of Information 2024; FDA 1993 irradiation memorandum).
  • Effect. Irradiation prevents proliferation of T lymphocytes, which is the immediate cause of TA-GVHD (Circular of Information 2024).
  • Validation. The dose actually delivered to the container is measured, for example with thermoluminescent dosimeter chips, and validated annually and after mechanical repairs. Radiation-sensitive indicators on each container are encouraged (FDA 1993 irradiation memorandum).
  • Labeling. Irradiated containers are permanently labeled "irradiated"; removable tie-tags are not acceptable (FDA 1993 irradiation memorandum; Circular of Information 2024).

Shelf life and potassium in irradiated red cells

  • Red cells. Irradiated red cells expire 28 days after irradiation, or on the original date if that is earlier (21 CFR 610.53; Circular of Information 2024).
  • Platelets and Liquid Plasma. Irradiation has no known adverse effect on these components, and their dating is unchanged (Circular of Information 2024).
  • Potassium. Irradiation damages the red cell membrane and raises supernatant potassium. Removal of the supernatant before transfusion may reduce the risk in patients prone to hyperkalemia (Circular of Information 2024; FDA 1993 irradiation memorandum).

Indications for irradiated cellular components

Irradiated whole blood, red cells, platelets, granulocytes and Liquid Plasma are indicated for patients at risk of TA-GVHD (Circular of Information 2024).

Recipient group Basis Source
Fetuses receiving intrauterine transfusion, and at-risk neonates Listed among recipients at greatest risk Circular of Information 2024
Recipients of hematopoietic progenitor cell transplants Severe cellular immunodeficiency Circular of Information 2024
Selected patients with severe congenital cellular immunodeficiency Inability to reject donor T cells Circular of Information 2024
Recipients of cellular components from a blood relative Donor homozygous for an HLA haplotype shared with the recipient Circular of Information 2024
Recipients of HLA-selected (HLA-matched) components Donor selected for HLA compatibility Circular of Information 2024
Recipients of granulocyte transfusions Granulocytes must be irradiated Circular of Information 2024
Patients receiving purine analogues (fludarabine, cladribine) or alemtuzumab or antithymocyte globulin Risk depends on clinical factors and the agent Circular of Information 2024

HIV infection is excepted from the severe cellular immunodeficiency group in the Circular. Leukoreduced components still carry enough T lymphocytes to cause TA-GVHD (Circular of Information 2024).

Washing of cellular components

  • Process. Cellular components are washed with 0.9% sodium chloride, with or without small amounts of dextrose. Only cellular components are washed (Circular of Information 2024).
  • What is removed. Washing removes plasma proteins, including antibodies, and glycerol from previously frozen red cells. Some red cells and platelets are lost, and platelet function falls through activation (Circular of Information 2024).
  • Shelf life. Washed components expire within 24 hours at 1–6 °C or 4 hours at 20–24 °C (Circular of Information 2024).
  • Indications. Washing removes plasma for rare recipients with anaphylactic or anaphylactoid reactions to plasma, and it removes additives such as mannitol (Circular of Information 2024). Washing for antibody removal, including for IgA-deficient recipients and maternal platelets in neonatal alloimmune thrombocytopenia, is covered in Blood Component Selection and Serologic Workup of Autoantibodies.
  • Limits. Leukocyte reduction requires a separate step; washing does not achieve it (Circular of Information 2024).

Volume reduction of cellular components

  • Process. Cellular components are centrifuged and part of the supernatant plasma and storage medium is removed aseptically, usually just before issue (Circular of Information 2024).
  • Indications and limits. Volume reduction is used when hypervolemia is a concern, such as in infants with compromised cardiac function. Its use for ABO incompatibility, circulatory overload and severe allergic reactions, and its limits, are covered in Blood Component Selection and Serologic Workup of Autoantibodies. Platelet function falls through activation (Circular of Information 2024).
  • Shelf life. Volume-reduced components expire within 24 hours at 1–6 °C or 4 hours at 20–24 °C (Circular of Information 2024).

CMV-safe components and prevention of transfusion-transmitted CMV

  • Source of CMV. CMV persists for life in mononuclear leukocytes of previously infected donors despite antibodies. Up to 70% of donors may be CMV seropositive (Circular of Information 2024).
  • Components that do not transmit CMV. Plasma, cryoprecipitate and other plasma-derived components are not associated with CMV transmission and need no CMV testing (Circular of Information 2024).
  • Two equivalent strategies. CMV-seronegative units are selected by testing donors for CMV antibody. Prestorage leukoreduction reduces CMV transmission to levels not significantly different from seronegative blood and is considered a suitable alternative (Circular of Information 2024).
  • At-risk recipients. CMV-seronegative or prestorage leukoreduced components are indicated for CMV-seronegative recipients at risk of severe infection: pregnant women and their fetuses, low-birthweight infants, recipients of hematopoietic progenitor cell or solid-organ transplants, severely immunosuppressed recipients and patients with HIV infection (Circular of Information 2024).
  • Pathogen reduction. Pathogen-reduced components may also be used where applicable (Circular of Information 2024).
  • Granulocytes. For a CMV-seronegative, severely immunosuppressed recipient, the use of CMV-seropositive granulocytes is evaluated carefully, because granulocytes cannot be leukoreduced (Circular of Information 2024).
  • Evidence. A systematic review for AABB of 11 studies found no significant difference in CMV infection between leukoreduced and CMV-seronegative components and no significant benefit from adding CMV testing to leukoreduction. The certainty of the evidence was low (Mainou 2016).

Pathogen reduction

Approved US pathogen reduction system and components

  • Mechanism. The current procedure adds a chemical photosensitizer to plasma or platelets, illuminates the bag with ultraviolet A light and removes unreacted photosensitizer and free photoproducts with a compound adsorption device (Circular of Information 2024).
  • Approved components. FDA has approved pathogen reduction of apheresis platelets and of whole-blood-derived or apheresis plasma. Pathogen-reduced plasma may be further made into PRCFC and Pathogen Reduced Plasma Cryoprecipitate Reduced. Products carry the attribute "psoralen-treated" (Circular of Information 2024).
  • Timing limits. Platelets are pathogen reduced within 24 hours of collection. Pathogen-reduced FFP is placed in the freezer within 8 hours of collection. The plasma device instructions require all steps, including freezing, within 24 hours of collection (FDA 2021 pathogen reduction Q&A).
  • Dating. Pathogen-reduced platelets carry a 5-day expiration. Extension beyond 5 days requires storage systems approved for that dating (FDA 2020 bacterial guidance).
  • US status. The INTERCEPT system (amotosalen and UVA light) became the first pathogen reduction technology approved by FDA, in 2014 (Lu 2020). The June 2024 Circular lists only psoralen-treated platelet and plasma products and no red cell or whole blood system (Circular of Information 2024). In the US MiPLATE trial of riboflavin-based Mirasol apheresis platelets, noninferiority was not shown: grade 2 or higher bleeding occurred in 40.0% versus 30.3% of patients, and corrected count increments were lower (Koepsell 2024).
  • Use. Facilities using pathogen-reduced platelets rose from 13% in 2019 to 60% in 2021 (Kracalik 2023).

Safety measures replaced by pathogen reduction

Measure replaced Condition Source
Irradiation of platelets for TA-GVHD Device labeling supports use as an alternative to gamma irradiation FDA 2021 pathogen reduction Q&A; Circular of Information 2024
Bacterial detection testing of platelets Platelets treated according to device instructions need no further bacterial control FDA 2020 bacterial guidance

Pathogen reduction of platelets and plasma also replaces Babesia NAT and the malaria travel deferral (Blood Donor Eligibility, Collection and Donor Infectious Disease Testing).

Limits and adverse effects of pathogen reduction

  • Resistant agents. No process eliminates all pathogens. Hepatitis A and E viruses, parvovirus B19, poliovirus and Bacillus cereus spores have resisted some processes (Circular of Information 2024).
  • Contraindications. Pathogen-reduced components are contraindicated in patients with hypersensitivity to amotosalen or other psoralens. They are contraindicated in neonates treated with phototherapy devices emitting a peak wavelength below 425 nm or a lower bandwidth bound below 375 nm, because of possible erythema (Circular of Information 2024).
  • Cardiac events. In a randomized trial of plasma exchange for thrombotic thrombocytopenic purpura, five patients receiving amotosalen-treated plasma and none receiving conventional plasma had cardiac adverse events, none fatal (Circular of Information 2024).
  • Red cells. No pathogen reduction system for red cells or whole blood is listed among FDA-approved products (Circular of Information 2024). In the phase 3 ReCePI trial in cardiac surgery, amustaline/glutathione-treated red cells were noninferior for acute kidney injury within 48 hours (29.3% vs 28.0%). Five of 159 recipients developed low-titer antibodies to treated red cells without hemolysis (Sekela 2025).

Bacterial risk control for platelets

Room-temperature platelets carry a higher risk of sepsis and related death than any other component. On the day of transfusion about 1 in 2,500 units is contaminated despite a single early culture. Reported septic reactions range from 1 in 100,000 by passive surveillance to 1 in 10,000 by active surveillance. With 5-day storage, 95–100% of septic reactions and all associated deaths followed transfusion of day 4 and day 5 platelets (FDA 2020 bacterial guidance).

Federal requirement. Collection establishments and transfusion services control the risk with FDA-approved or FDA-cleared devices or other FDA-acceptable methods. A contaminated unit and other components from the same collection are not released, and the organism is identified (21 CFR 606.145).

FDA strategies for apheresis platelets and prestorage pools

Strategies are from the 2020 FDA bacterial guidance.

Strategy Sampling Dating
Large-volume delayed sampling (LVDS) at ≥36 hours Single culture of ≥16 mL, aerobic and anaerobic, at least 36 hours after collection; 12-hour incubation before release 5 days
LVDS at ≥48 hours (apheresis only) Single culture of ≥16 mL, aerobic and anaerobic, at least 48 hours after collection Up to 7 days
Pathogen reduction (apheresis) None after treatment 5 days
Primary culture at ≥24 hours, then secondary culture on or after day 3 ≥16 mL primary; ≥8 mL aerobic secondary 5 days
Primary culture at ≥24 hours or LVDS at ≥36 hours, then secondary culture on or after day 4 (apheresis) ≥16 mL secondary, aerobic and anaerobic Up to 7 days
Primary culture at ≥24 hours or LVDS at ≥36 hours, then secondary rapid test Rapid test per device labeling Up to 7 days

FDA strategies for single and poststorage-pooled whole-blood-derived platelets

Strategy Dating
Rapid bacterial test Single units 5 days; poststorage pools expire 4 hours after pooling
Single aerobic culture at ≥36 hours 5 days
Single aerobic culture at ≥24 hours 5 days; secondary rapid testing may be considered after day 3
  • Extension beyond day 5. Extension to day 7 uses devices labeled as a safety measure and storage containers cleared for 7-day storage. The facility that performs secondary testing updates the label with the new expiration (FDA 2020 bacterial guidance).
  • Previous practice (before the 2019 guidance, implemented by October 1, 2021). A single culture sampled no sooner than 24 hours after collection supported 5-day dating. Septic reactions persisted at 1 in 100,000 to 1 in 10,000 under that approach (FDA 2020 bacterial guidance).
  • Cold storage. Cold storage at 1–6 °C is outside the scope of the bacterial guidance and is covered in Blood Component Preparation, Storage, Shelf Life and Quality Control.

Transfusion Indications, Massive Transfusion, Platelet Refractoriness and Patient Blood Management

Definition. A transfusion indication is the clinical and laboratory setting in which a blood component is expected to benefit the patient. In the United States, the indications, contraindications and doses of each component are stated in the Circular of Information for the Use of Human Blood and Blood Components (Circular of Information 2024). Hemoglobin thresholds for red cells follow the 2023 AABB International Guidelines (Carson 2023). Platelet count thresholds follow the 2025 AABB and International Collaboration for Transfusion Medicine Guidelines (ICTMG) guideline (Metcalf 2025). Patient blood management (PBM) is a patient-centered, systematic, evidence-based approach to improve outcomes by managing and preserving the patient's own blood while promoting patient safety and empowerment (Shander 2022).

Related page: Blood Component Selection and Serologic Workup of Autoantibodies (ABO and RhD selection for each component, emergency release and RhD-positive blood in massive hemorrhage) Related page: Transfusion Reactions (TACO, TRALI, febrile and allergic reactions and the metabolic effects of massive transfusion) Related page: The Rh Blood Group System: D, Weak and Partial D, RhCE Variants and Rh Typing Problems (RhCE variants and Rh alloimmunization in sickle cell disease) Related page: Pretransfusion Testing, Antibody Identification, Crossmatch and Drug Interference (sample requirements and crossmatch)

Red blood cell transfusion thresholds

Red-cell-containing components are indicated for a symptomatic or critical deficit of oxygen-carrying capacity and for red cell exchange. They are contraindicated for anemia that specific hematinic medications can correct (iron, vitamin B12, folic acid or erythropoietin) and for volume expansion alone (Circular of Information 2024).

The 2023 guideline is based on 45 randomized trials with 20,599 adult participants. Restrictive thresholds were typically 7–8 g/dL, and liberal thresholds were 9–10 g/dL. For most populations, restrictive thresholds did not adversely affect patient-important outcomes (moderate-quality evidence) (Carson 2023).

Population Threshold at which transfusion is considered Strength and certainty Source
Hospitalized adults who are hemodynamically stable Hemoglobin <7 g/dL Strong; moderate certainty Carson 2023
Adults undergoing cardiac surgery 7.5 g/dL may be chosen Follows the restrictive threshold of most trials Carson 2023
Adults undergoing orthopedic surgery or with preexisting cardiovascular disease 8 g/dL may be chosen Follows the restrictive threshold of most trials Carson 2023
Hospitalized adults with hematologic and oncologic disorders Hemoglobin <7 g/dL Conditional; low certainty Carson 2023
Critically ill children who are hemodynamically stable, without hemoglobinopathy, cyanotic cardiac disease or severe hypoxemia Hemoglobin <7 g/dL Strong; moderate certainty Carson 2023
Stable children with congenital heart disease 7 g/dL (biventricular repair), 9 g/dL (single-ventricle palliation), 7–9 g/dL (uncorrected disease) Conditional; low certainty Carson 2023
  • Previous rule (AABB 2016, replaced in 2023). The 2016 guideline recommended a threshold of 7 g/dL for hospitalized, hemodynamically stable adults, including the critically ill. It recommended 8 g/dL for orthopedic surgery, cardiac surgery and preexisting cardiovascular disease. Its recommendations did not apply to acute coronary syndrome, to severe thrombocytopenia in patients treated for hematologic or oncologic disorders, or to chronic transfusion-dependent anemia (Carson 2016). The 2023 guideline lowered the threshold that may be chosen in cardiac surgery to 7.5 g/dL and added recommendations for hematologic and oncologic disorders and for children (Carson 2023).
  • Storage age. The 2016 guideline recommended red cells selected at any point within the licensed dating period, including for neonates, because 13 trials with 5515 participants showed no benefit from fresher blood (Carson 2016).
  • Acute myocardial infarction. The MINT trial randomized 3504 patients with myocardial infarction and hemoglobin <10 g/dL to a restrictive strategy (cutoff 7 or 8 g/dL) or a liberal strategy (cutoff <10 g/dL). Myocardial infarction or death at 30 days occurred in 16.9% with the restrictive and 14.5% with the liberal strategy (risk ratio 1.15; 95% CI 0.99–1.34). The difference was not significant, and potential harm of the restrictive strategy was not excluded (MINT 2023).
  • Clinical context. Both guidelines state as good practice that the overall clinical context and alternative therapies are considered in each transfusion decision (Carson 2016; Carson 2023).

Results of major randomized trials that inform the restrictive thresholds are given as restrictive strategy versus liberal strategy.

Trial Population and hemoglobin thresholds Main result Source
TRICC 838 critically ill adults; 7.0 vs. 10.0 g/dL 30-day mortality 18.7% vs. 23.3% (P = 0.11); in-hospital mortality 22.3% vs. 28.1% Hébert 1999
FOCUS 2016 patients aged ≥50 years with cardiovascular disease or risk factors after hip-fracture surgery; symptoms or <8 vs. 10 g/dL Death or inability to walk without assistance at 60 days 34.7% vs. 35.2% Carson 2011
Upper gastrointestinal bleeding 921 patients with severe acute upper gastrointestinal bleeding; 7 vs. 9 g/dL 6-week survival 95% vs. 91% (hazard ratio for death 0.55); further bleeding 10% vs. 16% Villanueva 2013
TRISS 998 patients with septic shock; 7 vs. 9 g/dL 90-day mortality 43.0% vs. 45.0% (relative risk 0.94); median 1 vs. 4 units transfused in the ICU Holst 2014
TITRe2 2003 patients after cardiac surgery; 7.5 vs. 9 g/dL Serious infection or ischemic event 35.1% vs. 33.0%; deaths 4.2% vs. 2.6% (hazard ratio 1.64) Murphy 2015
TRICS III 5243 cardiac surgery patients at moderate to high risk; 7.5 vs. 9.5 g/dL (operating room and ICU) or 8.5 g/dL (ward) Death, myocardial infarction, stroke or new renal failure with dialysis 11.4% vs. 12.5% (noninferior); red cell transfusion 52.3% vs. 72.6% Mazer 2017

Platelet transfusion thresholds

The 2025 AABB/ICTMG guideline applied GRADE methods to 21 randomized trials and 13 observational studies. Restrictive strategies probably did not increase mortality or bleeding compared with liberal strategies, and spinal hematoma after lumbar puncture in thrombocytopenic patients was exceedingly rare (Metcalf 2025).

Setting 2025 AABB/ICTMG (Metcalf 2025) 2015 AABB (Kaufman 2015)
Hypoproliferative thrombocytopenia, nonbleeding, chemotherapy or allogeneic stem cell transplant Transfuse at <10 × 10³/µL (strong) Transfuse at ≤10 × 10³/µL (strong)
Hypoproliferative thrombocytopenia, nonbleeding adults, autologous stem cell transplant or aplastic anemia Prophylactic transfusion not recommended (conditional) Included in therapy-induced hypoproliferative thrombocytopenia: transfuse at ≤10 × 10³/µL (strong); aplastic anemia not addressed
Consumptive thrombocytopenia, adults without major bleeding Transfuse at <10 × 10³/µL (conditional) Not addressed
Consumptive thrombocytopenia, neonates without major bleeding Transfuse at <25 × 10³/µL (strong) Adults only
Dengue without major bleeding Not recommended (strong) Not addressed
Central venous catheter, compressible site Transfuse at <10 × 10³/µL (conditional) Transfuse at <20 × 10³/µL (weak)
Lumbar puncture Transfuse at <20 × 10³/µL (strong) Transfuse at <50 × 10³/µL (weak)
Interventional radiology <20 × 10³/µL low-risk; <50 × 10³/µL high-risk (conditional) Not addressed
Major nonneuraxial surgery Transfuse at <50 × 10³/µL (conditional) Transfuse at <50 × 10³/µL (weak)
Cardiovascular surgery without thrombocytopenia or major hemorrhage Not recommended (conditional) Routine prophylaxis not recommended with bypass (weak)
Nonoperative intracranial hemorrhage, platelet count >100 × 10³/µL, including antiplatelet agents Not recommended (conditional) No recommendation for or against with antiplatelet therapy
  • Previous rule (AABB 2015, replaced in 2025). The thresholds for central venous catheter placement (20 → 10 × 10³/µL) and lumbar puncture (50 → 20 × 10³/µL) were lowered. The 2015 guideline made no recommendation for or against platelets in intracranial hemorrhage on antiplatelet therapy, and the 2025 guideline recommends against them when the count exceeds 100 × 10³/µL (Kaufman 2015; Metcalf 2025). The 2015 guideline transfused all hospitalized adults with therapy-induced hypoproliferative thrombocytopenia, autologous transplant included, at ≤10 × 10³/µL. The 2025 guideline recommends against prophylactic platelets after autologous stem cell transplant and in aplastic anemia (conditional) (Kaufman 2015; Metcalf 2025). The 2015 guideline also recommended a dose of up to one apheresis unit or equivalent, because half a standard unit was equally effective (Kaufman 2015).
  • Dose and survival. Platelet content, dose and expected increment are given in Blood Component Preparation, Storage, Shelf Life and Quality Control. Transfused platelets survive 3–4 days, so prophylactic doses may need repetition in 1–3 days (Circular of Information 2024).
  • Contraindications. Platelets are not transfused for bleeding unrelated to platelet number or function, or at counts >100,000/µL without abnormal function. Prophylaxis is generally not indicated for antiplatelet medication or for dysfunction extrinsic to the platelet (uremia, certain types of von Willebrand disease, hyperglobulinemia). In heparin-induced thrombocytopenia, TTP and ITP, platelets are given only for life-threatening hemorrhage (Circular of Information 2024).

Major randomized trials of platelet transfusion gave the following results.

Trial Population and comparison Main result Source
PLADO 1272 patients with chemotherapy or stem cell transplant; prophylactic doses of 1.1, 2.2 or 4.4 × 10¹¹ platelets/m² at ≤10 × 10³/µL Grade ≥2 bleeding 71%, 69% and 70%; the low dose used fewer platelets and more transfusions. Bleeding occurred on 25% of days with counts ≤5 × 10³/µL and 17% of days with counts of 6–80 × 10³/µL Slichter 2010
TOPPS 600 patients aged ≥16 years with chemotherapy or stem cell transplant; no prophylaxis vs. prophylaxis at <10 × 10³/µL WHO grade 2–4 bleeding 50% vs. 43%; noninferiority of no prophylaxis not shown. Bleeding rates were similar after autologous transplant Stanworth 2013
PACER 338 patients with platelet counts of 10–50 × 10³/µL before ultrasound-guided central venous catheter placement; one platelet unit vs. none Grade 2–4 catheter-related bleeding 4.8% vs. 11.9%; withholding platelets did not meet the noninferiority margin van Baarle 2023
PATCH 190 adults with intracerebral hemorrhage on antiplatelet therapy; platelet transfusion vs. standard care Death or dependence at 3 months more frequent with platelet transfusion (adjusted common odds ratio 2.05) Baharoglu 2016

Plasma indications and reversal of vitamin K antagonists

Indication for Fresh Frozen Plasma Source
Preoperative or bleeding patients who need replacement of multiple coagulation factors (liver disease, DIC) Circular of Information 2024
Massive transfusion with clinically significant coagulation deficiency Circular of Information 2024
Warfarin therapy with bleeding or an invasive procedure before vitamin K can act, when only transient reversal is needed Circular of Information 2024
Transfusion or plasma exchange in TTP Circular of Information 2024
Congenital or acquired factor deficiency with no specific concentrate available Circular of Information 2024
Rare plasma protein deficiency, such as factor V deficiency, when recombinant products are unavailable Circular of Information 2024
  • Contraindications. Plasma is not indicated when specific therapy corrects the coagulopathy more effectively: vitamin K for urgent vitamin K antagonist reversal, Cryoprecipitated AHF or Pathogen Reduced Cryoprecipitated Fibrinogen Complex for hypofibrinogenemia, and specific factor concentrates. Specific reversal agents are used for non-vitamin-K anticoagulants, such as idarucizumab for dabigatran and andexanet for factor Xa inhibitors. Plasma is not used for volume expansion (Circular of Information 2024).
  • Minimally elevated INR. Plasma is not transfused to correct an INR of 1.7 or less. An INR of 1.5–1.7 represents at least 30% of coagulation factor levels, which allows normal hemostasis. A standard dose of about 15 mL/kg may not normalize such an INR (Circular of Information 2024).
  • Four-factor prothrombin complex concentrate (4F-PCC). In a randomized trial of 202 patients with major bleeding on vitamin K antagonists, 4F-PCC (factors II, VII, IX and X and proteins C and S) was noninferior to plasma for 24-hour hemostatic efficacy (72.4% vs. 65.4%). It was superior for rapid INR correction to ≤1.3 at 30 minutes after infusion (62.2% vs. 9.6%). Adverse events, including thromboembolic events, were similar (Sarode 2013).
  • 4F-PCC before urgent procedures. In 181 patients needing rapid vitamin K antagonist reversal before urgent surgery or an invasive procedure, effective hemostasis occurred in 90% with 4F-PCC and 75% with plasma. Rapid INR reduction to ≤1.3 at 30 minutes after infusion occurred in 55% and 10%. Fluid overload or similar cardiac events occurred in 3% and 13% (Goldstein 2015).

Cryoprecipitate and fibrinogen replacement

  • Content and dose. Fibrinogen and factor content, the dose of 1 bag per 7–10 kg and the expected fibrinogen rise are given in Blood Component Preparation, Storage, Shelf Life and Quality Control.
  • Indications. Cryoprecipitated AHF is used for bleeding associated with fibrinogen deficiency and when recombinant or virus-inactivated preparations of fibrinogen, factor VIII, factor XIII or von Willebrand factor are not readily available. It is second-line therapy for von Willebrand disease and hemophilia A, and it may be used for uremic bleeding after other treatments fail (Circular of Information 2024).
  • Pathogen Reduced Cryoprecipitated Fibrinogen Complex. It is indicated for bleeding, including massive hemorrhage, associated with fibrinogen deficiency, and for second-line therapy of von Willebrand disease (Circular of Information 2024).
  • Fibrinogen concentrate. In the FIBRES trial, 827 patients with bleeding and hypofibrinogenemia after cardiac surgery were randomized to fibrinogen concentrate (4 g) or cryoprecipitate (10 units) per dose, and 735 were treated and analyzed. Allogeneic components in the 24 hours after bypass averaged 16.3 and 17.0 units, which met the criterion for noninferiority. Thromboembolic events occurred in 7.0% and 9.6% (Callum 2019).
  • Fibrinogen in obstetric hemorrhage. In 128 women with postpartum hemorrhage, fibrinogen was the only marker associated with progression to severe hemorrhage. Each 1 g/L decrease raised the risk 2.63-fold, and a fibrinogen of ≤2 g/L had a positive predictive value of 100% for severe hemorrhage (Charbit 2007).

Massive transfusion and hemostatic resuscitation

Trial Design Main finding Source
PROPPR 680 severely injured patients predicted to need massive transfusion; plasma:platelets:red cells 1:1:1 or 1:1:2 No significant difference in 24-hour (12.7% vs. 17.0%) or 30-day mortality (22.4% vs. 26.1%). Hemostasis was achieved more often (86% vs. 78%), and death from exsanguination at 24 hours was less frequent (9.2% vs. 14.6%) with 1:1:1 Holcomb 2015
CRASH-2 20,211 bleeding trauma patients; tranexamic acid 1 g over 10 minutes and 1 g over 8 hours within 8 hours of injury All-cause mortality 14.5% vs. 16.0% (relative risk 0.91); death from bleeding 4.9% vs. 5.7% CRASH-2 2010
WOMAN 20,060 women with postpartum hemorrhage; tranexamic acid 1 g, with a second 1 g dose if bleeding continued Death from bleeding 1.5% vs. 1.9% (risk ratio 0.81), 1.2% vs. 1.7% when given within 3 hours of birth; hysterectomy not reduced WOMAN 2017
  • Component volumes in PROPPR. The 1:1:1 group received more plasma (median 7 vs. 5 units) and platelets (12 vs. 6 units) and the same red cells (9 units) in 24 hours. None of 23 prespecified complications differed (Holcomb 2015).
  • Timing of tranexamic acid. WOMAN concluded that tranexamic acid for postpartum hemorrhage should be given as soon as possible after bleeding begins (WOMAN 2017). In an exploratory analysis of CRASH-2, treatment within 1 hour of injury (relative risk 0.68) or at 1–3 hours (0.79) reduced death from bleeding, and treatment after 3 hours appeared to increase it (4.4% vs. 3.1%; relative risk 1.44) (CRASH-2 2011).
  • Viscoelastic testing. In a meta-analysis of 17 trials (1493 participants, mostly cardiac surgery), transfusion guided by thromboelastography or rotational thromboelastometry reduced the proportion of patients given red cells (relative risk 0.86), plasma (0.57) and platelets (0.73). Mortality was lower (3.9% vs. 7.4%), but the evidence was graded as low quality (Wikkelsø 2017).
  • Early plasma and platelet ratios. In the PROMMTT cohort of 905 transfused trauma patients at 10 US level I centers, higher plasma:red cell and platelet:red cell ratios were independently associated with lower 6-hour mortality. In the first 6 hours, patients with ratios below 1:2 were 3 to 4 times more likely to die than patients with ratios of 1:1 or higher. After 24 hours the ratios were not associated with mortality (Holcomb 2013).
  • Prehospital plasma. In the PAMPer cluster-randomized trial of 501 injured patients at risk for hemorrhagic shock, thawed plasma given during air medical transport lowered 30-day mortality from 33.0% to 23.2% (Sperry 2018).
  • Tranexamic acid in traumatic brain injury. CRASH-3 randomized 12,737 patients with traumatic brain injury. Among patients treated within 3 hours, head-injury-related death occurred in 18.5% with tranexamic acid and 19.8% with placebo (risk ratio 0.94; 95% CI 0.86–1.02). The risk ratio was 0.78 in mild-to-moderate and 0.99 in severe head injury. Vascular occlusive events and seizures were similar (CRASH-3 2019).
  • Tranexamic acid in gastrointestinal bleeding. HALT-IT randomized 12,009 patients to 1 g of tranexamic acid followed by 3 g over 24 hours, or placebo. Death from bleeding within 5 days occurred in 4% of each group (risk ratio 0.99). Venous thromboembolic events occurred in 0.8% with tranexamic acid and 0.4% with placebo (HALT-IT 2020).

Platelet refractoriness

Refractoriness is defined as repeated poor responses to platelet transfusion. In nonbleeding patients, one definition is 2 transfusion failures with ABO-identical platelets in a dose adapted to the patient's weight (Couvidou 2023). Nonimmune causes account for about 80% of cases, and they include infection, splenomegaly and other causes of platelet consumption (Couvidou 2023). Antibodies to class I HLA (A and B) cause most immune refractoriness, and antibodies to human platelet antigens (HPA) are less frequent (Cohn 2020).

Corrected count increment (CCI). CCI = (posttransfusion count − pretransfusion count, per µL) × body surface area (m²) ÷ platelets transfused (× 10¹¹). The CCI is usually measured 10–60 minutes after transfusion (Circular of Information 2024).

Finding Interpretation Source
CCI >7500 at 10 minutes to 1 hour and >4500 at 24 hours Typical response to conventional platelets in an afebrile, nonbleeding patient Circular of Information 2024
CCI <5000 at 10 minutes to 1 hour (below the expected >7500), with supportive serology May indicate immune refractoriness; the poor early recovery separates it from nonimmune causes Circular of Information 2024
Adequate 1-hour recovery with reduced 24-hour survival Nonimmune mechanisms (splenomegaly, sepsis, fever, intravascular devices, DIC) Circular of Information 2024
Refractoriness definition in the TRAP trial CCI <5000 Couvidou 2023

The Circular uses 7500 as the lower limit of the expected 1-hour response and <5000, with supportive serology, as the value that may indicate immune refractoriness (Circular of Information 2024).

  • Example calculation. A patient with a body surface area of 1.40 m² received 4.5 × 10¹¹ platelets. The count rose from 2000/µL to 29,000/µL at 15 minutes, which gives a CCI of 8400 (Circular of Information 2024).
  • Lower CCI without refractoriness. Multiple prior transfusions can lower the CCI. Component modifications that lower it are listed in Blood Component Modification: Leukoreduction, Irradiation, Washing, Volume Reduction, Pathogen Reduction and CMV-Safe Components (Circular of Information 2024).
  • Prevention by leukoreduction. In the TRAP trial, 530 patients receiving induction chemotherapy for acute myeloid leukemia were randomized to 4 platelet types. Lymphocytotoxic antibodies with refractoriness developed in 13% of controls, compared with 3% with filtered pooled platelets, 5% with ultraviolet B-irradiated pooled platelets and 4% with filtered apheresis platelets. Lymphocytotoxic antibodies developed in 45% of controls and 17–21% of the treated groups. Apheresis platelets from single random donors added no benefit over pooled leukoreduced platelets (TRAP 1997).
  • Selection of compatible platelets. Crossmatch-compatible or HLA-matched or HLA-compatible units support immune-refractory patients. When a "4 of 4" HLA-A and HLA-B match cannot be found, the antibody specificity prediction method selects units that lack the antigens recognized by the patient's antibodies (Cohn 2020). HLA and HPA typing, antibody identification and the platelet crossmatch help select units with acceptable survival (Circular of Information 2024).
  • ABO-nonidentical platelets. Selection rules, the positive DAT and hemolysis from incompatible plasma are described in Blood Component Selection and Serologic Workup of Autoantibodies and Transfusion Reactions.

Patient blood management and alternatives to allogeneic transfusion

The global definition of PBM names 3 areas: screening, diagnosis and treatment of anemia; minimizing surgical, procedural and iatrogenic blood loss and managing coagulopathic bleeding; and supporting the patient while treatment begins. The definition emphasizes informed choice (Shander 2022).

Strategy Evidence Source
Preoperative intravenous iron In PREVENTT, 487 anemic patients (hemoglobin <130 g/L in men and <120 g/L in women) received 1000 mg ferric carboxymaltose or placebo 10–42 days before major open abdominal surgery. Death or transfusion occurred in 29% and 28% (risk ratio 1.03), and iron was not superior to placebo Richards 2020
Intraoperative and postoperative cell salvage In 82 trials with 12,520 adults in elective surgery, the risk ratio for allogeneic red cell transfusion was 0.65 (very low-certainty evidence) Lloyd 2023
Acute normovolemic hemodilution in cardiac surgery In 19 studies with 9418 patients, allogeneic red cell transfusion fell from 31.5% to 27.6% (risk ratio 0.85). The RCT-only analysis was not significant (risk ratio 0.81; 95% CI 0.64–1.02) Elfiki 2026

Patients who decline transfusion

  • Major and minor fractions. "Major fractions" (red cells, white cells, platelets, plasma and whole blood) are unacceptable to essentially all practicing Jehovah's Witnesses. "Minor fractions" (albumin, immunoglobulins, cryoprecipitate, individual clotting factors, prothrombin complex concentrate and hemostatic agents) are left to personal conscience, and more than 90% accept some or all of them when counseled (Abib 2026).
  • Individual checklist. Each patient completes an individualized checklist of accepted products and procedures, entered into the medical record (Abib 2026).
  • Continuous-circuit techniques. Cell salvage, acute normovolemic hemodilution, cardiopulmonary bypass, hemodialysis and epidural blood patch keep blood in a continuous circuit and are personal-choice items. About 95% of patients accept cell salvage once the continuous circuit is explained (Abib 2026).
  • Autologous donation. Preoperative autologous donation was historically forbidden. A Governing Body update of March 20, 2026, made it a personal-conscience decision (Abib 2026).
  • Children. Since Prince v. Massachusetts (1944), US courts have held that parents cannot withhold lifesaving treatment from their children on religious grounds (Abib 2026).
  • Cell salvage contraindications. Absolute contraindications are patient refusal, sickle cell disease (sickle cell trait excluded) and gross bacterial contamination. Amniotic fluid and cancer surgery are relative contraindications mitigated by leukoreduction filtration (Abib 2026).

Transfusion in sickle cell disease and thalassemia

Recommendation in sickle cell disease Strength Source
Extended red cell antigen profile by genotype or serology at the earliest opportunity, at minimum C/c, E/e, K, Jkᵃ/Jkᵇ, Fyᵃ/Fyᵇ, M/N and S/s Conditional; very low certainty Chou 2020
Prophylactic matching for Rh (C, E or C/c, E/e) and K antigens in addition to ABO/RhD Strong; moderate certainty Chou 2020
Automated red cell exchange for chronic transfusion Conditional; very low certainty Chou 2020
Automated or manual red cell exchange for severe acute chest syndrome Conditional; very low certainty Chou 2020
Preoperative transfusion for surgery under general anesthesia lasting more than 1 hour, aiming for hemoglobin >9 g/dL Conditional; very low certainty Chou 2020
Immunosuppressive therapy for delayed hemolytic transfusion reaction with ongoing hyperhemolysis Conditional; very low certainty Chou 2020
  • Serologic phenotype after transfusion. A serologic phenotype may be inaccurate after transfusion in the previous 3 months. Genotyping gives more accurate C and Fyᵇ assignments (Chou 2020).
  • Preoperative exchange. Red cell exchange is used when a patient who needs preoperative transfusion has a hemoglobin level of more than 9–10 g/dL that precludes simple transfusion (Chou 2020).
  • Hyperhemolysis. The definition and first-line treatment are given in Transfusion Reactions. ASH 2020 lists eculizumab as second-line therapy (Chou 2020).
  • Red cell exchange technique. Exchange targets and replacement units are covered in Therapeutic Apheresis, ASFA Indications and Hematopoietic Progenitor Cell Products.
Recommendation in transfusion-dependent β-thalassemia Source
Extended red cell antigen typing before the first transfusion, at least Rh C, c, D, E, e and Kell (K, k) Musallam 2025
ABO- and RhD-compatible units, also matched for C, c, E, e and Kell Musallam 2025
Antibody screen and indirect antiglobulin or electronic crossmatch before each transfusion Musallam 2025
Leukoreduced red cells, preferably by prestorage filtration; washed red cells after severe allergic reactions Musallam 2025
Transfusion every 2–5 weeks to a pretransfusion hemoglobin of 9.5–10.5 g/dL Musallam 2025
Pretransfusion hemoglobin of 10–11 g/dL for heart disease, clinically significant extramedullary hematopoiesis or inadequate marrow suppression Musallam 2025

Hemolytic Disease of the Fetus and Newborn, Fetomaternal Hemorrhage, Rh Immune Globulin and Fetal and Neonatal Transfusion

Definition. Hemolytic disease of the fetus and newborn (HDFN) is destruction of fetal or neonatal red cells by maternal IgG alloantibodies. Maternal IgG binds the neonatal Fc receptor (FcRn) on placental syncytiotrophoblast and is transported into the fetal circulation. There it binds red cell antigens, and the coated cells are removed by macrophages in the fetal spleen and liver (Valentini 2025). Severe fetal anemia causes hydrops fetalis and intrauterine death. In neonates, HDFN is associated with kernicterus, which carries a high risk of long-term neurologic sequelae (Valentini 2025). Fetomaternal hemorrhage (FMH) is entry of fetal red cells into the maternal circulation. It is the immunizing event that Rh immune globulin (RhIG) prevents, and its volume determines the RhIG dose (Hajjaj 2025).

Related page: ABO and H Blood Group Systems and ABO Discrepancies (ABO HDFN in group A or B infants of group O mothers, and omission of reverse grouping in newborns) Related page: The Rh Blood Group System: D, Weak and Partial D, RhCE Variants and Rh Typing Problems (weak and partial D, RhIG candidacy by D type and fetal RHD genotyping on cell-free DNA) Related page: Kell, Duffy, Kidd, MNS, Lewis, I, P1PK and Other Blood Group Systems, Nomenclature and Genotyping (Kell, Kidd, Duffy and other antibodies) Related page: Immunohematology Methods in Red Cell Serology (titration method) Related page: Blood Component Selection and Serologic Workup of Autoantibodies (RhIG after RhD-positive transfusion in RhD-negative recipients) Related page: Blood Component Modification: Leukoreduction, Irradiation, Washing, Volume Reduction, Pathogen Reduction and CMV-Safe Components (irradiation and CMV-safe components)

Antibodies that cause hemolytic disease of the fetus and newborn

Antibody Frequency and features Source
Anti-D Most common cause; 64.1% of cases Valentini 2025
Anti-K Second most common; about 20% of severe HDFN in Western countries. Anemia is earlier and more severe, and intrauterine transfusion (IUT) is needed earlier and at lower maternal titers; the mechanism is described in Kell, Duffy, Kidd, MNS, Lewis, I, P1PK and Other Blood Group Systems, Nomenclature and Genotyping Valentini 2025
Anti-c Third most common Valentini 2025
Anti-k, -C, -E, -e, -Fyᵃ and -U Moderate-risk antibodies; 13.5% of cases. Anti-Fyᵃ uncommonly causes HDFN that needs IUT Valentini 2025
Anti-Jkᵃ and -Jkᵇ Usually mild hemolysis; severe cases are reported, particularly in the neonatal period Valentini 2025
Anti-I, -Le, -P1, -Lu and -Yt Antigens minimally expressed on fetal red cells; no clinically significant hemolysis Valentini 2025
Anti-A and anti-B ABO HDFN; usually mild (ABO and H Blood Group Systems and ABO Discrepancies) Valentini 2025
  • Effect of prophylaxis. Postpartum RhIG, introduced in the 1970s, reduced RhD alloimmunization in at-risk pregnancies from about 13–16% to about 0.5–1.8%. Routine antepartum RhIG lowered it further to 0.14–0.2% (ACOG Practice Bulletin 181, 2017).
  • Incidence. The incidence of HDFN is 3–80 per 100,000 live births in high-income countries and 252–529 per 100,000 in developing nations (Valentini 2025).

Monitoring of the alloimmunized pregnancy

  • Maternal titers. In a first alloimmunized pregnancy, titers are repeated every 4 weeks until 24 (sometimes 28) weeks and then every 2 weeks until delivery or until the critical titer is reached (Valentini 2025). The titer is a doubling dilution in the indirect antiglobulin test, described in Immunohematology Methods in Red Cell Serology.
  • Critical titer. The critical titer is the level at which the fetus is at risk of moderate to severe anemia. An international Delphi panel set it at ≥16 for non-Kell antibodies (Mustafa 2025). For anti-K the critical titer is lower, usually 4 (Valentini 2025). ASFA gives typical critical titers of 8–32 and states that the titer does not always correlate with risk or severity, for example with anti-Kell (Zantek 2026).
  • Fetal antigen status. In the Delphi consensus, 75.3% of experts agreed on cell-free DNA (cfDNA) testing to determine fetal antigen status, particularly for RhD, Kell and c (Mustafa 2025). PCR-based cfDNA genotyping for RhD, C, c, E and Kell has a reported sensitivity of 99% or above. Specificity is 99% for RhD and 100% for the other antigens (Valentini 2025).
  • Paternal testing. RHD zygosity of an RhD-positive partner is determined by genotyping because no anti-d reagent exists. Kell and Rh C/c and E/e zygosity can sometimes be estimated serologically because antisera exist for both antithetical antigens. Paternal testing is reliable only when paternity is confirmed (Valentini 2025).
Fetal surveillance recommendation Source
Middle cerebral artery peak systolic velocity (MCA-PSV) by Doppler is the primary technique to detect fetal anemia SMFM 2015
Amniotic fluid ΔOD450 is not used to diagnose fetal anemia SMFM 2015
MCA-PSV is reserved for pregnancies at risk of an anemic fetus and measured close to the vessel's origin, ideally at a 0° angle without angle correction SMFM 2015
MCA-PSV >1.5 multiples of the median (MoM) or hydrops: fetal blood sampling with preparation for IUT, unless delivery carries less risk SMFM 2015
MCA-PSV or a predicted decline in fetal hemoglobin times the second IUT SMFM 2015
A fetus at significant risk of anemia is delivered at 37–38 weeks unless indications develop earlier SMFM 2015
  • Accuracy of MCA-PSV. In a meta-analysis, MCA-PSV ≥1.5 MoM had a sensitivity of 86% and a specificity of 71% for moderate to severe anemia in fetuses not previously transfused (Valentini 2025).
  • Original MCA-PSV validation study. In 111 fetuses at risk from maternal red cell alloimmunization, with hemoglobin measured by cordocentesis, an increased MCA-PSV detected moderate or severe anemia with a sensitivity of 100% in the presence or absence of hydrops. The false-positive rate was 12% (Mari 2000).

Intrauterine transfusion and antenatal immunomodulation

Parameter Value Source
Earliest gestational age for IUT 16–18 weeks Mustafa 2025
Latest gestational age for IUT 35 0/7 to 35 6/7 weeks Mustafa 2025
Procedure risk Fetal demise risk is higher before 18–20 weeks Valentini 2025
Post-IUT target Hemoglobin 14–16 g/dL or hematocrit 40–45% Valentini 2025
Hydrops at the first IUT Posttransfusion hemoglobin does not exceed 4 times the starting level Valentini 2025
Timing of delivery after IUT Usually 3 weeks after the last IUT, around 37 weeks Valentini 2025
  • Intravenous immunoglobulin (IVIG). IVIG reduces transplacental IgG transport and phagocytosis of antibody-coated fetal red cells. Serial IVIG postpones the first IUT by about 15–22 days compared with the previous affected pregnancy, and 1 g/kg weekly is commonly used (Valentini 2025). In the Delphi consensus, 70.0% agreed on maternal IVIG after a previous IUT before 24 weeks or a fetal or neonatal death from HDFN (Mustafa 2025).
  • Therapeutic plasma exchange. The most common regimen is 3 sessions between 10 and 14 weeks followed by IVIG (Valentini 2025). ASFA classifies TPE for HDFN as category III, grade 2C, in the 10th edition. Its category is the same as in the 9th edition (Zantek 2026).
  • Nipocalimab. Nipocalimab is an FcRn blocker. UNITY was an open-label, single-group phase 2 study in 13 pregnancies at high risk of recurrent early-onset severe HDFN, with intravenous nipocalimab 30 or 45 mg/kg weekly from 14 to 35 weeks. Live birth at ≥32 weeks without IUT occurred in 7 of 13 (54%), against a historical benchmark of 0% (Moise 2024). The phase 3 AZALEA trial is ongoing, and FDA has granted Breakthrough Therapy designation (Bhatt 2026). It remains investigational for HDFN (Valentini 2025; Bhatt 2026).
  • Long-term outcome after IUT. The LOTUS study assessed 291 children treated with IUT at a median age of 8.2 years. Neurodevelopmental impairment occurred in 4.8%: cerebral palsy in 2.1%, severe developmental delay in 3.1% and bilateral deafness in 1.0%. Among preoperative factors, severe hydrops was independently associated with impairment (odds ratio 11.2) (Lindenburg 2012).

Postnatal management and exchange transfusion

  • Cord blood studies. Cord blood at delivery is tested for blood type, DAT, total bilirubin and reticulocyte count as a baseline (Valentini 2025).
  • Treatment frequency. In older series, 30–60% of affected neonates needed exchange transfusion and more than 95% received phototherapy (Valentini 2025). Exchange transfusion is now uncommon: in the Netherlands in 2011–2021 it was performed in 6.8% of RhD-alloimmunized pregnancies, and the number of hospitals performing it fell by 56% (de Winter 2026). IUT suppresses fetal erythropoiesis, which prolongs postnatal anemia and increases top-up transfusions (Valentini 2025).
  • Exchange transfusion. A double-volume exchange of 160–180 mL/kg lowers bilirubin, removes maternal IgG and replaces antigen-positive neonatal red cells with antigen-negative donor red cells (de Winter 2026).
Exchange transfusion finding Value Source
Adverse events Thrombocytopenia 31–90%, hypocalcemia 1–47%, leukocytopenia 33%, sepsis 10% de Winter 2026
Frequency in D-mediated HDFN (Netherlands, 11 years) 6.8% (85 of 1247 pregnancies) de Winter 2026
Frequency in c-mediated HDFN 2.4% (16 of 665 pregnancies) de Winter 2026
Frequency with a maximum maternal anti-D titer ≤32 0.9% (5 of 558) de Winter 2026
Frequency with a maximum maternal anti-D titer of 64 4.8% (7 of 143) de Winter 2026
  • Delphi consensus on the neonate. Anemia studies are performed before discharge (92.0% agreement) and repeated within 1 week of discharge after IUT (84.0%). Exchange transfusions are centralized in experienced hospitals (96.0%). The hemoglobin cutoff for transfusion after discharge is 7 g/dL (92.0%), and infants are monitored until 2–3 months of age (96.0%) (Mustafa 2025).

Fetomaternal hemorrhage: screening and quantification

Test Principle Output and turnaround Limitations Source
Rosette test Anti-D coats RhD-positive fetal cells in maternal blood; RhD-positive indicator cells form rosettes Qualitative screen; 15 minutes to 1 hour; detects 5 mL of fetal red cells (10 mL of whole blood) False negative with fetal RhD variants; false positive with maternal weak or partial D or a positive DAT; unusable in RhD-positive mothers or with an RhD-negative fetus Hajjaj 2025
Kleihauer-Betke test (KBT) HbA is eluted by acid; HbF resists elution, so fetal cells stain pink and maternal cells appear pale Quantitative; about 2 hours Interobserver variability; overestimates FMH when maternal F cells are increased (hemoglobinopathies, hereditary persistence of fetal hemoglobin, pregnancy) Hajjaj 2025
Flow cytometry Fluorescent anti-HbF, anti-D or anti-carbonic anhydrase; fetal red cells lack carbonic anhydrase Quantitative; availability limited (4% of US and 13% of Canadian laboratories) May still overestimate FMH with increased maternal F cells Hajjaj 2025
  • Calculation. The simplest formula is: percentage of fetal red cells × 5000 mL (mean maternal blood volume) = FMH volume in mL of fetal whole blood (Hajjaj 2025). In the Canadian survey, 67% of laboratories used this CAP/AABB formula (Hajjaj 2025). A fixed volume of 5000 mL may underestimate FMH in women with larger blood volumes (Hajjaj 2025).
  • Dose from the FMH volume. Number of 1500 IU (300 µg) vials = FMH volume (mL of whole blood) ÷ 30. Technical guidance rounds up when the decimal is ≥0.5 and then adds 1 vial (Hajjaj 2025).
  • Example calculation. A KBT of 0.5% gives 0.5% × 5000 mL = 25 mL of fetal whole blood. Then 25 ÷ 30 = 0.83, which rounds to 1, and 1 vial is added, for a total of 2 vials.
  • Frequency of large FMH. FMH is below 30 mL in preterm deliveries and in 99.0–99.67% of term deliveries (Hajjaj 2025). An FMH beyond the coverage of one 1500 IU dose occurs in about 1–3 per 1000 pregnancies (Hajjaj 2025).
  • Gestational age for testing. The Society of Obstetricians and Gynaecologists of Canada recommends FMH testing beyond standard dosing after 20 weeks, when fetal blood volume can exceed the coverage of a standard dose (Hajjaj 2025).

Rh immune globulin: dose, timing and indications

Item Rule Source
Protective dose 20 µg protects against 1 mL of RhD-positive fetal red cells; a 1500 IU (300 µg) vial covers 30 mL of fetal whole blood or 15 mL of fetal red cells Hajjaj 2025
Antenatal, single-dose regimen 300 µg at 28 weeks; Valentini 2025 names the United States, United Kingdom, Netherlands and Germany Valentini 2025
Antenatal, 2-dose regimen 100 µg at 28 and 34 weeks; Valentini 2025 describes it as more common in France and Canada Valentini 2025
Postpartum 300 µg within 72 hours of delivery of an RhD-positive neonate Valentini 2025
Missed 72-hour window Given as soon as the need is recognized, up to 28 days after delivery (Society of Obstetricians and Gynaecologists of Canada) Hajjaj 2025
Other sensitizing events Threatened abortion, antepartum bleeding, ectopic pregnancy, fetal demise, blunt abdominal trauma, external cephalic version and invasive diagnostic procedures Valentini 2025
  • Abortion or pregnancy loss before 12 weeks (ACOG Clinical Practice Update, online September 2024; December 2024 issue). The ACOG Clinical Practice Update recommends forgoing routine Rh testing and RhIG for abortion and early pregnancy loss before 12 weeks of gestation. RhIG may still be considered on an individual basis (ACOG 2024; Wong 2025). The update revised Practice Bulletins 181, 200 and 225 (ACOG 2024).
  • Previous rule. Before this update, RhIG was recommended routinely after first-trimester abortion or miscarriage. Valentini 2025 describes the supporting evidence as weak and outdated. Practice Bulletin 181 (2017) stated that evidence was insufficient that a threatened pregnancy loss before 12 weeks requires RhIG (Wong 2025).
  • Other societies. The Society of Family Planning (2022) stated that forgoing RhIG before 12 weeks is highly unlikely to increase anti-D formation. It recommends 50 µg (250 IU) for ectopic pregnancy, sharp curettage and other invasive procedures. The Society for Maternal-Fetal Medicine recommends offering Rh testing and RhIG for abortion before 12 weeks when feasible (Wong 2025).
  • Shortage measures (ACOG Practice Advisory, 2024). During RhIG shortages, ACOG lists neonatal RhD typing on cord blood before the postpartum dose and omission of antenatal prophylaxis when paternity is certain and the partner is RhD-negative. It lists cfDNA testing for fetal RhD status as a reasonable way to prioritize RhIG, and it prioritizes postpartum doses, with the 28-week dose given when supply allows (ACOG Practice Advisory 2024). Commercial laboratories offer fetal RhD genotyping as part of cfDNA aneuploidy screening (Grace 2025).

Fetal and neonatal alloimmune thrombocytopenia

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is severe fetal thrombocytopenia from maternal alloantibodies against human platelet antigens (HPA), with a risk of intracranial hemorrhage (Pothof 2025).

Recommendation Source
Fetal HPA typing, by noninvasive methods if quality-assured, when the father is unknown, unavailable or heterozygous for the implicated antigen Lieberman 2019
IVIG from as early as 12 weeks in subsequent affected pregnancies after a previous child with FNAIT-related intracranial hemorrhage Lieberman 2019
HPA-selected platelets available at delivery for potentially affected infants Lieberman 2019
Unselected platelets when HPA-selected platelets are not immediately available Lieberman 2019
Anti-HPA-1a antibody level to identify high-risk pregnancies; no cutoff value defined Pothof 2025
  • Screening. No FNAIT screening program exists, and at-risk pregnancies are identified after the birth of an affected child (Pothof 2025). A 2025 Delphi panel reached consensus on a screening design based only on anti-HPA-1a antibody levels (Pothof 2025).
  • Maternal platelets. Washing of maternal platelets for neonatal alloimmune thrombocytopenia is described in Blood Component Modification: Leukoreduction, Irradiation, Washing, Volume Reduction, Pathogen Reduction and CMV-Safe Components.
  • Incidence. In six prospective studies of 59,425 unselected newborns, severe thrombocytopenia occurred in 0.15%, and FNAIT caused 27% of these cases. Intracranial hemorrhage, likely of antenatal origin, occurred in 25% of the FNAIT cases. Intracranial hemorrhage from FNAIT was estimated at 10 per 100,000 neonates (Kamphuis 2014).
  • Norwegian HPA-1a screening study. In a research screening and intervention program, HPA-1 typing of 100,448 pregnant women found 2.1% HPA-1a-negative, and 10.6% of these had anti-HPA-1a. Immunized women were delivered by cesarean section 2–4 weeks before term, with HPA-1a-negative platelets reserved for the newborn. Compared with historical controls, severe FNAIT-related complications fell from 10 of 51 to 3 of 57 (Kjeldsen-Kragh 2007).
  • Antenatal IVIG. Seven women with a previous severely affected infant received antenatal IVIG, with or without dexamethasone. In the 6 fetuses sampled, the platelet count rose by a mean of 72.5 × 10³/µL. All 7 infants had counts above 30 × 10³/µL at birth and none had intracranial hemorrhage. Three of their 7 untreated siblings had intracranial hemorrhage (Bussel 1988).

Neonatal transfusion thresholds and doses

Trial or guideline Population and comparison Result Source
PlaNeT-2 660 infants born before 34 weeks with severe thrombocytopenia; platelet thresholds 50 × 10³/µL vs. 25 × 10³/µL Death or new major bleeding within 28 days: 26% vs. 19% (odds ratio 1.57) Curley 2019
TOP 1824 infants ≤1000 g, 22–28 weeks; higher vs. lower hemoglobin thresholds Death or neurodevelopmental impairment 50.1% vs. 49.8% Kirpalani 2020
ETTNO 1013 infants 400–999 g; liberal vs. restrictive red cell thresholds Death or disability at 24 months 44.4% vs. 42.9% Franz 2020

The platelet threshold for neonates in the AABB/ICTMG 2025 guideline is given in Transfusion Indications, Massive Transfusion, Platelet Refractoriness and Patient Blood Management.

Postnatal age TOP higher threshold, hemoglobin (g/dL), with / without respiratory support TOP lower threshold, hemoglobin (g/dL), with / without respiratory support Source
Up to 7 days 13 / 12 11 / 10 Meyer 2022
8–14 days 12.5 / 11 10 / 8.5 Meyer 2022
14–21 days and >21 days 11 / 10 8.5 / 7 Meyer 2022
  • Separation of the TOP groups. Pretransfusion mean hemoglobin differed by 1.9 g/dL between the TOP groups (Kirpalani 2020).
  • ETTNO thresholds. ETTNO set hematocrit thresholds by postnatal age and critical or noncritical condition. Converted to hemoglobin, the liberal thresholds were 13.7/11.6 g/dL (critical/noncritical) up to day 7, 12.2/10.3 g/dL from days 8 to 21 and 11.3/9.4 g/dL after day 21. The restrictive thresholds were 11.3/9.4, 10/8.1 and 9/6.9 g/dL (Meyer 2022).
  • PINT. The PINT trial randomized 451 infants with birth weight <1000 g to low or high hemoglobin thresholds. Death or severe retinopathy, bronchopulmonary dysplasia or brain injury occurred in 74.0% with the low and 69.7% with the high threshold (P = 0.25). Fewer infants in the low-threshold group were transfused (89% vs. 95%) (Kirpalani 2006).
  • Pretransfusion testing in infants younger than 4 months. In a 2026 laboratory study, infants younger than 4 months had forward ABO typing only. The laboratory protocol and the Korean transfusion guideline did not require reverse typing at that age, and passively acquired maternal IgG complicates its interpretation (Ji 2026). Isoagglutinin development is described in ABO and H Blood Group Systems and ABO Discrepancies. A pediatric guideline adapted in Egypt places the antibody screen on the maternal sample when available, collected within 3 days before delivery or after delivery (Mokhtar 2024).
Pediatric dose (patients <50 kg) Expected increment Source
Plasma, 10–15 mL/kg Factor level rise of 15–20% Circular of Information 2024
Platelets, 5–10 mL/kg or 1 unit per 10 kg (patients >10 kg) Platelet rise of 50,000–100,000/µL Circular of Information 2024
Cryoprecipitated AHF, 1–2 units per 10 kg Fibrinogen rise of 60–100 mg/dL Circular of Information 2024

Therapeutic Apheresis, ASFA Indications and Hematopoietic Progenitor Cell Products

Definition. Therapeutic apheresis (TA) is a group of extracorporeal procedures that separate blood into its components and remove or treat one of them. Therapeutic plasma exchange (TPE) separates plasma by membrane filtration or centrifugation, removes it and replaces it with albumin, plasma or a crystalloid or colloid solution. Exchange of more than 2 plasma volumes in one session is called high-volume TPE (Zantek 2026). The American Society for Apheresis (ASFA) assigns each indication a category and a grade of recommendation. The 10th special issue (2026) contains 93 fact sheets and 183 graded indications. It replaced the 9th special issue (2023) (Zantek 2026; Connelly-Smith 2023). Hematopoietic progenitor cell (HPC) products are collected from marrow, mobilized peripheral blood by apheresis or umbilical cord blood. They are regulated in the United States under 21 CFR 1271 (21 CFR 1271.3).

Related page: Blood Component Selection and Serologic Workup of Autoantibodies (ABO and RhD selection of components and autoimmune hemolytic anemia serology) Related page: Transfusion Indications, Massive Transfusion, Platelet Refractoriness and Patient Blood Management (simple transfusion and antigen matching in sickle cell disease and thalassemia) Related page: Transfusion Reactions (citrate toxicity and allergic reactions to plasma) Related page: Hemolytic Disease of the Fetus and Newborn, Fetomaternal Hemorrhage, Rh Immune Globulin and Fetal and Neonatal Transfusion (TPE and intravenous immunoglobulin in hemolytic disease of the fetus and newborn)

Apheresis procedures and terminology

Procedure What is removed or treated Source
Therapeutic plasma exchange (TPE) Plasma, replaced with albumin, plasma or crystalloid or colloid Zantek 2026
Double filtration plasmapheresis (DFPP) Plasma components larger than the pore size of a second filter, after membrane separation of plasma Zantek 2026
Immunoadsorption (IA) Immunoglobulins and immune complexes bound to ligands in an adsorber column; no plasma replacement needed Zantek 2026
Lipoprotein apheresis (LA) Lipoprotein particles, by filtration, precipitation or adsorption, without replacement fluid Zantek 2026
Red cell exchange Patient red cells, replaced with donor red cells Zantek 2026
Erythrocytapheresis Red cells, replaced with crystalloid or colloid when necessary Zantek 2026
Leukocytapheresis White cells, such as leukemic blasts Zantek 2026
Thrombocytapheresis Platelets Zantek 2026
Extracorporeal photopheresis (ECP) Buffy coat treated with a photoactive compound (such as a psoralen) and ultraviolet A light, then reinfused in the same procedure Zantek 2026
  • Preferred term. ASFA prefers "therapeutic plasma exchange." "Plasmapheresis" is historically nonspecific and can refer to any procedure that removes plasma, including donor procedures (Zantek 2026).
  • DFPP and TPE. TPE removes all plasma components without selection. DFPP removes only high-molecular-weight components larger than the filter pore size, so DFPP does not generally replace TPE (Zantek 2026).

Kinetics of plasma exchange

  • Removal per procedure. One plasma volume exchanged reduces the intravascular concentration of a substance by about 63%, although the reduction differs among molecules (Zrimsek 2026). Exchange of 1–1.5 plasma volumes clears about 63–78% of a plasma constituent in a single procedure (Nadim 2026).
  • Usual dose. Most ASFA fact sheets specify 1–1.5 total plasma volumes per TPE (Zantek 2026).
  • Distribution of the target. IgM is 75–80% intravascular, so 1–2 TPE procedures are usually enough for symptomatic hyperviscosity in Waldenström macroglobulinemia. IgG is 45–65% intravascular, and 4–5 procedures may be needed for IgG hyperviscosity (Zantek 2026). Each TPE lowers viscosity by 20–30% (Zantek 2026).
  • Rebound. After TPE for Waldenström macroglobulinemia, IgM returns to baseline in about 3–5 weeks, so systemic therapy follows (Zantek 2026).
  • Timing with rituximab. Rituximab binds CD20-positive lymphocytes immediately, and an interval of 18–24 hours between rituximab infusion and TPE is used in practice (Zantek 2026).

ASFA categories and grades

Category Definition Source
I Apheresis accepted as first-line therapy, alone or with other treatments Zantek 2026
II Apheresis accepted as second-line therapy, alone or with other treatments Zantek 2026
III Optimum role of apheresis not established; decisions are individualized Zantek 2026
IV Published evidence shows or suggests apheresis is ineffective or harmful; IRB or ethics committee approval is desirable if apheresis is undertaken Zantek 2026
  • Grades. Grades follow GRADE: 1 is a strong and 2 a weak recommendation, and A, B and C denote high, moderate and low or very low quality evidence (Zantek 2026).
  • Distribution in the 10th edition. There are 29 category I, 49 category II, 102 category III and 3 category IV indications. The category definitions have been unchanged since the 5th edition (Zantek 2026).
  • New fact sheets. The 2 new fact sheets are "Hemoglobinopathies, non-sickle cell" and "Myelin oligodendrocyte glycoprotein antibody-associated disease" (Zantek 2026).

Category changes from the 9th edition (2023) to the 10th edition (2026)

Indication (10th edition wording) 9th edition (2023) 10th edition (2026) Source
Acute liver failure, fulminant; standard-volume TPE III, 2B II, 1B Zantek 2026
Acute liver failure, fulminant; high-volume TPE I, 1A II, 1A Zantek 2026
Paraproteinemic and autoimmune demyelinating neuropathies, IgM related; TPE I, 1B (IgG/IgA/IgM combined) III, 1C Zantek 2026
Neuromyelitis optica spectrum disorder, acute attack or relapse; TPE and IA II (TPE 1B, IA 1C) I (TPE 1B, IA 1C) Zantek 2026
Sepsis with thrombocytopenia-associated multiorgan failure (new subset); TPE III, 2A (sepsis with multiorgan failure) II, 2B Zantek 2026
Sepsis with multiorgan failure without thrombocytopenia-associated multiorgan failure; TPE III, 2A III, 2B Zantek 2026
Steroid-responsive encephalopathy associated with autoimmune thyroiditis; TPE II, 2C III, 2C Zantek 2026
Liver transplantation, antibody-mediated rejection, ABO-incompatible living donor; TPE III, 2C (all liver AMR) I, 1C Zantek 2026
Lung transplantation, desensitization; TPE III, 2C II, 1C Zantek 2026
ANCA-associated vasculitis with severe or rapidly deteriorating kidney function or dialysis, diffuse alveolar hemorrhage, or refractory disease; TPE III (MPA 1B, GPA 1B, EGPA 2C) II, 1B Zantek 2026
  • Retired indication. RhD alloimmunization prophylaxis after transfusion (category IV) was retired in the 10th edition. Its last full fact sheet appeared in the 9th edition (2023) (Zantek 2026).
  • ANCA-associated vasculitis. The category was lowered after the PEXIVAS trial (2020) and raised to II in 2026 in line with the KDIGO guideline (Zantek 2026).

Selected ASFA indications (10th edition)

Table 7 of the 10th edition lists every category change from the 9th edition. Indications below that are absent from the category-change table kept their 9th-edition category; grades can differ (Zantek 2026).

System Indication; procedure Category, grade Source
Hematologic Thrombotic thrombocytopenic purpura; TPE I, 1A Zantek 2026
Hematologic Complement-mediated TMA, factor H autoantibody; TPE I, 2C Zantek 2026
Hematologic Drug-induced TMA, ticlopidine; TPE I, 2B Zantek 2026
Hematologic Drug-induced TMA, clopidogrel; TPE III, 2B Zantek 2026
Hematologic Drug-induced TMA, gemcitabine or quinine; TPE IV, 2C Zantek 2026
Hematologic STEC-HUS, severe; TPE or IA III, 2C Zantek 2026
Hematologic Hyperviscosity in hypergammaglobulinemia, symptomatic; TPE I, 1B Zantek 2026
Hematologic Hyperviscosity, prophylaxis for rituximab; TPE I, 1C Zantek 2026
Hematologic Severe cold agglutinin disease; TPE II, 2C Zantek 2026
Hematologic Post-transfusion purpura; TPE III, 2C Zantek 2026
Neurologic Guillain-Barré syndrome, acute; TPE I, 1A Zantek 2026
Neurologic Chronic inflammatory demyelinating polyradiculoneuropathy; TPE or IA I, 1B Zantek 2026
Neurologic Myasthenia gravis, acute short-term treatment; TPE, DFPP or IA I, 1B Zantek 2026
Neurologic NMDA receptor antibody encephalitis; TPE, IA or DFPP I, 1C Zantek 2026
Neurologic Multiple sclerosis, acute attack or relapse; TPE II, 1A Zantek 2026
Neurologic Lambert-Eaton myasthenic syndrome; TPE II, 2C Zantek 2026
Renal Anti-glomerular basement membrane disease with diffuse alveolar hemorrhage; TPE I, 1C Zantek 2026
Renal Anti-glomerular basement membrane disease, dialysis-independent; TPE I, 1B Zantek 2026
Renal Anti-glomerular basement membrane disease, dialysis-dependent without hemorrhage; TPE III, 2B Zantek 2026
Renal Recurrent focal segmental glomerulosclerosis in a kidney transplant; TPE or IA I, 1B Zantek 2026
Renal Myeloma cast nephropathy; TPE II, 2B Zantek 2026
Rheumatologic Catastrophic antiphospholipid syndrome; TPE I, 2C Zantek 2026
Rheumatologic Systemic lupus erythematosus, severe; TPE, IA or DFPP II, 2C Zantek 2026
Rheumatologic Cryoglobulinemia, symptomatic and severe; TPE or DFPP II, 2A Zantek 2026
Transplantation ABO-compatible kidney, antibody-mediated rejection; TPE, IA or DFPP I, 1B Zantek 2026
Transplantation ABO-incompatible kidney, living-donor desensitization; TPE, IA or DFPP I, 1B Zantek 2026
Hepatic Wilson disease, fulminant; TPE I, 1C Zantek 2026
Metabolic Homozygous familial hypercholesterolemia; LA I, 1A Zantek 2026
Metabolic Lipoprotein(a) hyperlipoproteinemia with progressive atherosclerotic disease; LA II, 1B Zantek 2026
Dermatologic Erythrodermic mycosis fungoides or Sézary syndrome; ECP I, 1B Zantek 2026
Transplantation Graft-versus-host disease, acute or chronic; ECP II, 1B Zantek 2026
Dermatologic Psoriasis; TPE IV, 2C Zantek 2026

Plasma exchange in thrombotic thrombocytopenic purpura

  • Pathogenesis. Immune TTP results from IgG autoantibodies against ADAMTS13, with ADAMTS13 activity below 10% in most cases. Untreated TTP has a mortality of about 90%, and TPE lowered it to <10–20% (Zantek 2026).
  • Timing. Treatment for presumed TTP starts within 4–8 hours of suspicion, after other causes of TMA are judged unlikely, without waiting for ADAMTS13 results (Zantek 2026). If TPE is not immediately available, plasma infusion of 25–30 mL/kg is given if tolerated (Zantek 2026).
  • ISTH diagnostic strategy (2020). A plasma sample for ADAMTS13 testing is drawn before TPE or any blood product. In patients with a high pretest probability (≥90%), TPE and corticosteroids start before results. ADAMTS13 activity <10 IU/dL (<10%) is a positive result, and >20 IU/dL (>20%) is a negative result that prompts other diagnoses. Caplacizumab is not used where ADAMTS13 testing is unavailable (Zheng 2020).
  • Replacement fluid and schedule. TPE uses plasma or plasma and albumin, 1–1.5 plasma volumes daily, until the platelet count is >150 × 10⁹/L and LDH is near normal for 2–3 consecutive days (Zantek 2026). TPE provides ADAMTS13 and removes anti-ADAMTS13 autoantibodies (Zantek 2026).
  • Caplacizumab. In the HERCULES trial, caplacizumab shortened time to platelet count normalization (2.69 vs. 2.88 days). The composite of TTP-related death, recurrence or major thromboembolic event fell from 49% to 12%, and recurrence fell from 38% to 12%. Mucocutaneous bleeding occurred in 65% vs. 48% (Scully 2019).
  • Congenital TTP. Simple plasma infusion (10–15 mL/kg), cryosupernatant or plasma-derived von Willebrand factor concentrates have been used. Recombinant ADAMTS13 is FDA-approved for congenital TTP (Zantek 2026).

Replacement fluids, adverse events and vascular access

  • Coagulation factor depletion. Daily TPE depletes coagulation factors, especially fibrinogen, and plasma or cryoprecipitate supplementation may be considered (Zantek 2026). A pre-TPE fibrinogen threshold of 1.0 g/L is the most widely accepted cutoff for factor replacement (Zrimsek 2026).
  • Coagulation testing. An ASFA Choosing Wisely working group advised against coagulation tests during a course of 1.0–1.5 plasma volume exchanges unless the procedures are daily (Zrimsek 2026).
  • Plasma replacement. Allergic and citrate reactions are more frequent in TTP because of the large plasma volumes, and, because plasma replacement already contains citrate, less ACD-A is used per volume of blood processed (a higher inlet whole blood:ACD-A ratio) to reduce citrate reactions (Zantek 2026).
  • Immunoadsorption. IA needs no plasma replacement. Fibrinogen falls by about 30% in a single IA procedure in which 2–3 plasma volumes are processed (Zrimsek 2026).
  • Angiotensin-converting enzyme inhibitors. These drugs are absolutely contraindicated with adsorption-based LA, because bradykinin generation causes profound hypotension (Zantek 2026).
  • ECP precautions. ECP is contraindicated in aphakia and after splenectomy. Patients use eye and skin protection for 24 hours because of psoralen photosensitivity (Zantek 2026).
Study Population Findings Source
Single-center TPE review, 2018–2022 1219 TPE treatments in 145 patients Most common complications: depletion coagulopathy (47.6%), hypocalcemia (44.1%) and hypokalemia (36.6%); 98% of treatments via a central line Warner 2025
Single-center TA review, 1986–2016 14,082 procedures in 1132 patients Hypotension and mild allergic reactions were the most common adverse events. At the start of a course, access was a central venous catheter in 57%, a catheter with a peripheral vein in 27% and an arteriovenous fistula in 6% Jerman 2026
  • Access for chronic red cell exchange. Chronic vascular access is a concern in red cell exchange. Apheresis-compatible ports have been used in adults, with longer procedures and more complications (Zantek 2026).

Red cell exchange and erythrocytapheresis

Indication Target or rule Category, grade Source
Sickle cell disease, acute stroke HbS <30%, end hematocrit 30 ± 3% I, 1C Zantek 2026
Sickle cell disease, severe acute chest syndrome HbS <30% II, 1C Zantek 2026
Sickle cell disease, stroke prophylaxis HbS (or HbS + HbC) <30%; some aim for <15% so the next pre-procedure HbS is <30% I, 1A Zantek 2026
Sickle cell disease, preoperative management Individualized III, 2A Zantek 2026
Severe babesiosis Considered with parasitemia >10%, severe hemolysis or severe lung, kidney or liver compromise III, 2C Zantek 2026
Severe malaria Hyperparasitemia >10%; stopped after clinical improvement or <1% residual parasitemia III, 2B Zantek 2026
Polycythemia vera Erythrocytapheresis; hematocrit target <45% I, 1B Zantek 2026
Hereditary hemochromatosis Erythrocytapheresis of 350–800 mL of red cells every 2–3 weeks I, 1B Zantek 2026
  • Replacement units in sickle cell disease. Red cells are HbS-negative, leukocyte-reduced and antigen-matched (for example C/c, E/e and K). The end hematocrit is kept at ≤33% to avoid hyperviscosity (Zantek 2026).
  • Severe malaria. The CDC no longer recommends exchange transfusion for severe malaria. A CDC analysis of 101 patients given exchange transfusion and 314 not given it found no difference in mortality, and intravenous artesunate is the treatment (Zantek 2026).
  • Stroke prevention. In the STOP trial, chronic monthly transfusion in children with elevated transcranial Doppler velocities reduced stroke risk by 90% (Zantek 2026).
  • Polycythemia vera target. In a randomized trial of 365 patients, a hematocrit target <45% gave lower rates of cardiovascular death and major thrombosis than 45–50% (Zantek 2026).
  • Therapeutic phlebotomy in hemochromatosis. Phlebotomy is recommended when ferritin is ≥300 ng/mL in men or ≥200 ng/mL in premenopausal women. Typically 500 mL of whole blood is removed weekly or every 2 weeks until ferritin is <50 ng/mL (Zantek 2026). In a randomized trial of 38 patients, erythrocytapheresis reached ferritin ≤50 ng/mL in 9 procedures over 20 weeks, compared with 27 phlebotomies over 34 weeks (Zantek 2026).

Cytapheresis, photopheresis and lipoprotein apheresis

  • Leukocytapheresis for hyperleukocytosis (III, 2B). One procedure lowers the white cell count by 30–60%. Definitive chemotherapy is not delayed to arrange leukocytapheresis, and the European LeukemiaNet does not recommend the procedure. In acute myeloid leukemia, it is stopped when leukostasis resolves or the count is <50 × 10⁹/L, or <100 × 10⁹/L for prophylaxis. In acute lymphoblastic leukemia, the stopping point is <400 × 10⁹/L (Zantek 2026). Meta-analyses showed no reduction in early mortality (Zantek 2026).
  • Thrombocytapheresis. Symptomatic thrombocytosis is category II, 2C. Prophylactic and secondary thrombocytosis are category III, 2C (Zantek 2026).
  • Extracorporeal photopheresis. Mononuclear cells are usually collected from about 1.5 L of processed whole blood. Treatments are given in cycles of 2 per week (Zantek 2026).
  • Lipoprotein apheresis. Selective LA lowers LDL cholesterol by more than 60–70% per session. Long-term LA reduces atherosclerotic cardiovascular event rates by 50–85% (Zantek 2026).
FDA indication group for LA in familial hypercholesterolemia Criteria Source
A Homozygous familial hypercholesterolemia with LDL cholesterol >500 mg/dL Zantek 2026
B Heterozygous familial hypercholesterolemia with LDL cholesterol ≥300 mg/dL Zantek 2026
C Heterozygous familial hypercholesterolemia with LDL cholesterol ≥70 mg/dL and documented coronary or peripheral artery disease Zantek 2026
D Heterozygous familial hypercholesterolemia with lipoprotein(a) ≥60 mg/dL and documented coronary or peripheral artery disease Zantek 2026

Hematopoietic progenitor cell products

Regulation. HCT/Ps include hematopoietic stem and progenitor cells derived from peripheral and cord blood. Minimally manipulated bone marrow for homologous use that is not combined with another article is excluded from the definition (21 CFR 1271.3). An HCT/P is regulated solely under section 361 of the Public Health Service Act when it is minimally manipulated, intended for homologous use and not combined with another article. An HCT/P with a systemic effect also needs autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use (21 CFR 1271.10). For donors of peripheral blood progenitor cells, the infectious disease testing specimen may be collected up to 30 days before recovery (21 CFR 1271.80). Accreditation standards for collection, processing and administration are the FACT-JACIE International Standards, ninth edition (FACT 2026).

Product Red cell content Source
HPC, Apheresis Hematocrit 2–5%; usually <20 mL of red cells Zantek 2026
HPC, Marrow 25–35% red cells by volume Zantek 2026
HPC, Cord Blood Too few intact red cells to cause hemolysis Zantek 2026
  • Mobilization and collection. G-CSF at 10 µg/kg daily for 4 or 5 days is a common mobilization regimen. In patients with more than 1 previous line of therapy, prior melphalan or more than 4 cycles of lenalidomide, monitoring of the peripheral blood CD34+ count with preemptive plerixafor leads to successful collection in most patients (Mohammadi 2017). The peripheral blood CD34+ count before apheresis is the strongest predictor of poor collection (Mohty 2014).
  • CD34+ cell dose. The commonly accepted minimum dose is 2 × 10⁶ CD34+ cells/kg. For allogeneic transplantation in adults, 4–5 × 10⁶ CD34+ cells/kg is the most accepted dose, and more than 8 × 10⁶/kg may increase extensive chronic GVHD without improving survival (Mohammadi 2017).
  • CD34 enumeration. The ISHAGE guideline is a 4-parameter flow cytometric method for counting CD34+ cells in peripheral blood and apheresis products, validated in a multicenter North American study (Sutherland 1996).
  • Processing for ABO incompatibility. Red cells are depleted from the product in major incompatibility. Most institutions limit red cells in an HPC product to 20–30 mL, or 0.2–0.4 mL/kg in children. In minor incompatibility, the product's plasma is reduced when the donor isoagglutinin titer is >128 and the plasma volume is >200 mL (Zantek 2026).

ABO-incompatible HPC transplantation and passenger lymphocyte syndrome

HLA and ABO genes are inherited independently, and about half of allogeneic HPC transplants are ABO-incompatible (Zantek 2026).

Type Definition Complications Source
Major Recipient has anti-A or anti-B against donor red cells (for example, group O recipient of a group A graft) Acute hemolysis of red cells in the product, mainly with marrow; delayed red cell engraftment in up to 20–30%; pure red cell aplasia in 8–26% Zantek 2026
Minor Donor product contains anti-A or anti-B against recipient red cells (for example, group A recipient of a group O graft) Acute hemolysis at infusion when the donor titer is >128 and plasma volume >200 mL; passenger lymphocyte syndrome Zantek 2026
Bidirectional Both major and minor incompatibility Both sets of complications Zantek 2026
  • Passenger lymphocyte syndrome. Donor B lymphocytes in the graft produce anti-A or anti-B against host red cells. The syndrome typically occurs 7–10 days after transplant and can cause severe, potentially fatal hemolysis. Plasma reduction of the product does not remove the B lymphocytes or prevent the syndrome (Zantek 2026).
  • Apheresis in major incompatibility. TPE before infusion lowers recipient IgM or IgG titers to <16. Replacement fluid is albumin, or albumin with plasma compatible with both donor and recipient. TPE is category II, 1B for marrow grafts and II, 2B for apheresis grafts (Zantek 2026).
  • Apheresis in minor incompatibility. Red cell exchange with group O red cells to ≤35% residual recipient red cells mitigates delayed hemolysis in high-risk patients (category III, 2C) (Zantek 2026).
  • Pure red cell aplasia. It results from persistent recipient isohemagglutinins that destroy donor erythroid precursors. Pure red cell aplasia usually resolves after early withdrawal of cyclosporine. TPE is category III, 2C (Zantek 2026).

Component selection until conversion to donor type. Red cells are compatible with the recipient's isohemagglutinins, and plasma-containing components are compatible with both donor and recipient red cells (Matteocci 2024).

Incompatibility (example) Red cells Platelets, first choice Plasma, first choice Source
Major (recipient O, donor A) Recipient type (O) until anti-A disappears, then donor type Donor type (A) Donor type (A); AB second choice Matteocci 2024
Minor (recipient A, donor O) Donor type (O) Recipient type (A) Recipient type (A); AB second choice Matteocci 2024
Bidirectional (recipient A, donor B) O AB AB Matteocci 2024
  • Switch to donor-type red cells. The switch requires disappearance of isohemagglutinins against the donor ABO type, a negative DAT and 2 consecutive samples with forward and reverse typing that confirm the donor group (Matteocci 2024).
  • Group A2 platelets. Platelets from group A2 donors do not express A antigen, which extends platelet options (Matteocci 2024).

References

  1. AABB, American Red Cross, America's Blood Centers, Armed Services Blood Program. Circular of Information for the Use of Human Blood and Blood Components. June 2024. https://www.aabb.org/news-resources/resources/circular-of-information
  2. AABB. Association Bulletin #17-02: Updated strategies to limit or prevent iron deficiency in blood donors. March 16, 2017; updated March 2026. https://www.aabb.org/docs/default-source/default-document-library/resources/association-bulletins/ab17-02.pdf
  3. Abib A, Hensley NB, Resar LMS, Frank SM. What to do when you can't transfuse: update on optimizing outcomes for Jehovah's Witness patients. Hematol Rep. 2026;18(5):69. doi:10.3390/hematolrep18050069. PMID 42931033
  4. American College of Obstetricians and Gynecologists. ACOG Clinical Practice Update: Rh D immune globulin administration after abortion or pregnancy loss at less than 12 weeks of gestation. Obstet Gynecol. 2024;144(6):e140–e143. doi:10.1097/AOG.0000000000005733. PMID 39255498
  5. American College of Obstetricians and Gynecologists. Practice Advisory: Rho(D) immune globulin shortages. March 2024. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2024/03/rhod-immune-globulin-shortages
  6. American College of Obstetricians and Gynecologists. Practice Bulletin No. 181: Prevention of Rh D alloimmunization. Obstet Gynecol. 2017;130(2):e57–e70. doi:10.1097/AOG.0000000000002232. PMID 28742673
  7. Baharoglu MI, Cordonnier C, Al-Shahi Salman R, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet. 2016;387(10038):2605–2613. doi:10.1016/S0140-6736(16)30392-0. PMID 27178479
  8. Barty RL, Gagliardi K, Owens W, et al. A benchmarking program to reduce red blood cell outdating: implementation, evaluation, and a conceptual framework. Transfusion. 2015;55(7):1621–1627. doi:10.1111/trf.13055. PMID 25773353
  9. Bhatt AH, Nimbalkar SM, Patel DV, et al. Nipocalimab in early-onset severe hemolytic disease of the fetus and newborn. Pediatr Discov. 2026;4(3):e70067. doi:10.1002/pdi3.70067. PMID 42798736
  10. Bolan CD, Greer SE, Cecco SA, et al. Comprehensive analysis of citrate effects during plateletpheresis in normal donors. Transfusion. 2001;41(9):1165–1171. doi:10.1046/j.1537-2995.2001.41091165.x. PMID 11552076
  11. Bussel JB, Berkowitz RL, McFarland JG, et al. Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med. 1988;319(21):1374–1378. doi:10.1056/NEJM198811243192103. PMID 3141811
  12. Cable RG, Glynn SA, Kiss JE, et al. Iron deficiency in blood donors: the REDS-II Donor Iron Status Evaluation (RISE) study. Transfusion. 2012;52(4):702–711. doi:10.1111/j.1537-2995.2011.03401.x. PMID 22023513
  13. Callum J, Farkouh ME, Scales DC, et al. Effect of fibrinogen concentrate vs cryoprecipitate on blood component transfusion after cardiac surgery: the FIBRES randomized clinical trial. JAMA. 2019;322(20):1966–1976. doi:10.1001/jama.2019.17312. PMID 31634905
  14. Carson JL, Brooks MM, Hébert PC, et al. (MINT). Restrictive or liberal transfusion strategy in myocardial infarction and anemia. N Engl J Med. 2023;389(26):2446–2456. doi:10.1056/NEJMoa2307983. PMID 37952133
  15. Carson JL, Guyatt G, Heddle NM, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA. 2016;316(19):2025–2035. doi:10.1001/jama.2016.9185. PMID 27732721
  16. Carson JL, Stanworth SJ, Guyatt G, et al. Red blood cell transfusion: 2023 AABB international guidelines. JAMA. 2023;330(19):1892–1902. doi:10.1001/jama.2023.12914. PMID 37824153
  17. Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med. 2011;365(26):2453–2462. doi:10.1056/NEJMoa1012452. PMID 22168590
  18. Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost. 2007;5(2):266–273. doi:10.1111/j.1538-7836.2007.02297.x. PMID 17087729
  19. Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4(2):327–355. doi:10.1182/bloodadvances.2019001143. PMID 31985807
  20. Cohn CS. Platelet transfusion refractoriness: how do I diagnose and manage? Hematology Am Soc Hematol Educ Program. 2020;2020(1):527–532. doi:10.1182/hematology.2020000137. PMID 33275694
  21. Connelly-Smith L, Alquist CR, Aqui NA, et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Writing Committee of the American Society for Apheresis: the ninth special issue. J Clin Apher. 2023;38(2):77–278. doi:10.1002/jca.22043. PMID 37017433
  22. Cooper DJ, McQuilten ZK, Nichol A, et al. Age of red cells for transfusion and outcomes in critically ill adults. N Engl J Med. 2017;377(19):1858–1867. doi:10.1056/NEJMoa1707572. PMID 28952891
  23. Couvidou A, Rojas-Jiménez G, Dupuis A, et al. Anti-HLA class I alloantibodies in platelet transfusion refractoriness: from mechanisms and determinants to therapeutic prospects. Front Immunol. 2023;14:1125367. doi:10.3389/fimmu.2023.1125367. PMID 36845153
  24. CRASH-2 collaborators, Roberts I, Shakur H, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011;377(9771):1096–1101. doi:10.1016/S0140-6736(11)60278-X. PMID 21439633
  25. CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23–32. doi:10.1016/S0140-6736(10)60835-5. PMID 20554319
  26. CRASH-3 trial collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet. 2019;394(10210):1713–1723. doi:10.1016/S0140-6736(19)32233-0. PMID 31623894
  27. Curley A, Stanworth SJ, Willoughby K, et al. Randomized trial of platelet-transfusion thresholds in neonates. N Engl J Med. 2019;380(3):242–251. doi:10.1056/NEJMoa1807320. PMID 30387697
  28. de Winter DP, de Haas M, Hulzebos CV, et al. Antenatal risk estimation for exchange transfusions in neonates with hemolytic disease of the fetus and newborn in a changing treatment landscape. Transfusion. 2026;66(2):296–305. doi:10.1111/trf.70056. PMID 41468257
  29. Di Angelantonio E, Thompson SG, Kaptoge S, et al. Efficiency and safety of varying the frequency of whole blood donation (INTERVAL): a randomised trial of 45 000 donors. Lancet. 2017;390(10110):2360–2371. doi:10.1016/S0140-6736(17)31928-1. PMID 28941948
  30. Distler P. ISBT 128: a global information standard. Cell Tissue Bank. 2010;11(4):365–373. doi:10.1007/s10561-010-9196-2. PMID 20652420
  31. Eder AF, Hillyer CD, Dy BA, Notari EP 4th, Benjamin RJ. Adverse reactions to allogeneic whole blood donation by 16- and 17-year-olds. JAMA. 2008;299(19):2279–2286. doi:10.1001/jama.299.19.2279. PMID 18492969
  32. Elfiki M, Elfeky A, Ali MS, et al. Clinical effectiveness of acute normovolemic hemodilution in cardiac surgery: a systematic review and meta-analysis. Anesth Analg. 2026 (online ahead of print). doi:10.1213/ANE.0000000000008221. PMID 42442348
  33. Fergusson D, Hébert PC, Lee SK, et al. Clinical outcomes following institution of universal leukoreduction of blood transfusions for premature infants. JAMA. 2003;289(15):1950–1956. doi:10.1001/jama.289.15.1950. PMID 12697797
  34. Foundation for the Accreditation of Cellular Therapy. FACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, Processing and Administration, Ninth Edition. Accessed November 10, 2026. https://www.factglobal.org/standards/
  35. Franz AR, Engel C, Bassler D, et al. Effects of liberal vs restrictive transfusion thresholds on survival and neurocognitive outcomes in extremely low-birth-weight infants: the ETTNO randomized clinical trial. JAMA. 2020;324(6):560–570. doi:10.1001/jama.2020.10690. PMID 32780138
  36. Goldstein JN, Refaai MA, Milling TJ Jr, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015;385(9982):2077–2087. doi:10.1016/S0140-6736(14)61685-8. PMID 25728933
  37. Grace MR, Goodhue B, Vora NL. Rho(D) immune globulin shortage and fetal Rh(D) screening with cell-free DNA. Curr Opin Obstet Gynecol. 2025;37(2):55–59. doi:10.1097/GCO.0000000000001011. PMID 39774459
  38. Hajjaj OI, Callum J, Shehata N, et al. Laboratory assessment of fetomaternal haemorrhage and Rh immune globulin management: Canadian practice and scoping review. Br J Haematol. 2025;207(3):723–736. doi:10.1111/bjh.20246. PMID 40616214
  39. HALT-IT Trial Collaborators. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet. 2020;395(10241):1927–1936. doi:10.1016/S0140-6736(20)30848-5. PMID 32563378
  40. Hébert PC, Fergusson D, Blajchman MA, et al. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA. 2003;289(15):1941–1949. doi:10.1001/jama.289.15.1941. PMID 12697796
  41. Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 1999;340(6):409–417. doi:10.1056/NEJM199902113400601. PMID 9971864
  42. Heddle NM, Cook RJ, Arnold DM, et al. Effect of short-term vs. long-term blood storage on mortality after transfusion. N Engl J Med. 2016;375(20):1937–1945. doi:10.1056/NEJMoa1609014. PMID 27775503
  43. Holcomb JB, del Junco DJ, Fox EE, et al. The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks. JAMA Surg. 2013;148(2):127–136. doi:10.1001/2013.jamasurg.387. PMID 23560283
  44. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471–482. doi:10.1001/jama.2015.12. PMID 25647203
  45. Holst LB, Haase N, Wetterslev J, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med. 2014;371(15):1381–1391. doi:10.1056/NEJMoa1406617. PMID 25270275
  46. Jerman A, Andonova M, Čede AŽ, et al. Three decades of experience with therapeutic apheresis at a tertiary academic center: review of indications, clinical practice, special age groups and complications. BMC Nephrol. 2026;27(1):103. doi:10.1186/s12882-026-04750-2. PMID 41530746
  47. Ji E, Oh SH, Lee SM, Kim IS, et al. Optimising the workflow for infant ABO blood typing: the role of automated analyser and a manual reflex protocol. Transfus Med. 2026;36(5):484–491. doi:10.1111/tme.70081. PMID 42050373
  48. Joint UKBTS Professional Advisory Committee. Concessionary Release Limits for Leucocyte Depletion. October 2015. https://assets.publishing.service.gov.uk/media/5a7f53a2e5274a2e8ab4b7fe/JPAC_-_Concessionary_Release_Limits_for_Leucocyte_Depletion_-_October_2015.pdf
  49. Kamel H, Tomasulo P, Bravo M, et al. Delayed adverse reactions to blood donation. Transfusion. 2010;50(3):556–565. doi:10.1111/j.1537-2995.2009.02397.x. PMID 19804573
  50. Kamphuis MM, Paridaans NP, Porcelijn L, et al. Incidence and consequences of neonatal alloimmune thrombocytopenia: a systematic review. Pediatrics. 2014;133(4):715–721. doi:10.1542/peds.2013-3320. PMID 24590747
  51. Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015;162(3):205–213. doi:10.7326/M14-1589. PMID 25383671
  52. Kirpalani H, Bell EF, Hintz SR, et al. Higher or lower hemoglobin transfusion thresholds for preterm infants. N Engl J Med. 2020;383(27):2639–2651. doi:10.1056/NEJMoa2020248. PMID 33382931
  53. Kirpalani H, Whyte RK, Andersen C, et al. The Premature Infants in Need of Transfusion (PINT) study: a randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants. J Pediatr. 2006;149(3):301–307. doi:10.1016/j.jpeds.2006.05.011. PMID 16939737
  54. Kiss JE, Brambilla D, Glynn SA, et al. Oral iron supplementation after blood donation: a randomized clinical trial. JAMA. 2015;313(6):575–583. doi:10.1001/jama.2015.119. PMID 25668261
  55. Kjeldsen-Kragh J, Killie MK, Tomter G, et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood. 2007;110(3):833–839. doi:10.1182/blood-2006-08-040121. PMID 17429009
  56. Koepsell SA, Stolla M, Sedjo RL, et al. Results of clinical effectiveness of conventional versus Mirasol-treated apheresis platelets in patients with hypoproliferative thrombocytopenia (MiPLATE) trial. Transfusion. 2024;64(3):457–465. doi:10.1111/trf.17720. PMID 38314476
  57. Kracalik I, Sapiano MRP, Wild RC, et al. Supplemental findings of the 2021 National Blood Collection and Utilization Survey. Transfusion. 2023;63(Suppl 4):S19–S42. doi:10.1111/trf.17509. PMID 37702255
  58. Lacroix J, Hébert PC, Fergusson DA, et al. Age of transfused blood in critically ill adults. N Engl J Med. 2015;372(15):1410–1418. doi:10.1056/NEJMoa1500704. PMID 25853745
  59. Lieberman L, Greinacher A, Murphy MF, et al. Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach. Br J Haematol. 2019;185(3):549–562. doi:10.1111/bjh.15813. PMID 30828796
  60. Lindenburg IT, Smits-Wintjens VE, van Klink JM, et al. Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus/newborn: the LOTUS study. Am J Obstet Gynecol. 2012;206(2):141.e1–141.e8. doi:10.1016/j.ajog.2011.09.024. PMID 22030316
  61. Lloyd TD, Geneen LJ, Bernhardt K, et al. Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery. Cochrane Database Syst Rev. 2023;9(9):CD001888. doi:10.1002/14651858.CD001888.pub5. PMID 37681564
  62. Lu W, Fung M. Platelets treated with pathogen reduction technology: current status and future direction. F1000Res. 2020;9:F1000 Faculty Rev-40. doi:10.12688/f1000research.20816.1. PMID 32047608
  63. Mainou M, Alahdab F, Tobian AA, et al. Reducing the risk of transfusion-transmitted cytomegalovirus infection: a systematic review and meta-analysis. Transfusion. 2016;56(6 Pt 2):1569–1580. doi:10.1111/trf.13478. PMID 26826015
  64. Mari G, Deter RL, Carpenter RL, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. N Engl J Med. 2000;342(1):9–14. doi:10.1056/NEJM200001063420102. PMID 10620643
  65. Matteocci A, Pierelli L. Immuno-hematologic complexity of ABO-incompatible allogeneic HSC transplantation. Cells. 2024;13(10):814. doi:10.3390/cells13100814. PMID 38786038
  66. Mazer CD, Whitlock RP, Fergusson DA, et al. Restrictive or liberal red-cell transfusion for cardiac surgery. N Engl J Med. 2017;377(22):2133–2144. doi:10.1056/NEJMoa1711818. PMID 29130845
  67. Metcalf RA, Nahirniak S, Guyatt G, et al. Platelet transfusion: 2025 AABB and ICTMG international clinical practice guidelines. JAMA. 2025;334(7):606–617. doi:10.1001/jama.2025.7529. PMID 40440268
  68. Meyer MP, O'Connor KL, Meyer JH. Thresholds for blood transfusion in extremely preterm infants: a review of the latest evidence from two large clinical trials. Front Pediatr. 2022;10:957585. doi:10.3389/fped.2022.957585. PMID 36204671
  69. Mohammadi S, Malek Mohammadi A, Nikbakht M, et al. Optimizing stem cells mobilization strategies to ameliorate patient outcomes: a review of guidelines and recommendations. Int J Hematol Oncol Stem Cell Res. 2017;11(1):78–88. PMID 28286619
  70. Mohty M, Hübel K, Kröger N, et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014;49(7):865–872. doi:10.1038/bmt.2014.39. PMID 24686988
  71. Moise KJ Jr, Ling LE, Oepkes D, et al. Nipocalimab in early-onset severe hemolytic disease of the fetus and newborn. N Engl J Med. 2024;391(6):526–537. doi:10.1056/NEJMoa2314466. PMID 39115062
  72. Mokhtar G, Adly A, Baky AA, Ezzat D, et al. Transfusion of blood components in pediatric age groups: an evidence-based clinical practice guideline adapted for the use in Egypt using 'Adapted ADAPTE'. Ann Hematol. 2024;103(4):1373–1388. doi:10.1007/s00277-024-05657-4. PMID 38388746
  73. Murphy GJ, Pike K, Rogers CA, et al. Liberal or restrictive transfusion after cardiac surgery. N Engl J Med. 2015;372(11):997–1008. doi:10.1056/NEJMoa1403612. PMID 25760354
  74. Musallam KM, Cappellini MD, Porter JB, et al. TIF guidelines for the management of transfusion-dependent β-thalassemia. Hemasphere. 2025;9(3):e70095. doi:10.1002/hem3.70095. PMID 40045934
  75. Mustafa HJ, Sambatur EV, Shamshirsaz AA, et al. Monitoring and management of hemolytic disease of the fetus and newborn based on an international expert Delphi consensus. Am J Obstet Gynecol. 2025;232(3):280–300. doi:10.1016/j.ajog.2024.11.003. PMID 39547350
  76. Nadim M, Mirzabeigi Y, Akgun Y, et al. Plasma exchange for hantavirus pulmonary syndrome: a mechanistic case for an untested intervention. J Clin Apher. 2026;41(5):e70187. doi:10.1002/jca.70187. PMID 42806477
  77. Newman BH, Waxman DA. Blood donation-related neurologic needle injury: evaluation of 2 years' worth of data from a large blood center. Transfusion. 1996;36(3):213–215. doi:10.1046/j.1537-2995.1996.36396182137.x. PMID 8604504
  78. Pothof R, van den Akker-van Marle EM, de Vos TW, et al. Rising to the challenge: an international Delphi consensus study on fetal and neonatal alloimmune thrombocytopenia. Lancet Haematol. 2025;12(4):e304–e311. doi:10.1016/S2352-3026(25)00029-8. PMID 40175002
  79. Richards T, Baikady RR, Clevenger B, et al. Preoperative intravenous iron to treat anaemia before major abdominal surgery (PREVENTT): a randomised, double-blind, controlled trial. Lancet. 2020;396(10259):1353–1361. doi:10.1016/S0140-6736(20)31539-7. PMID 32896294
  80. Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128(11):1234–1243. doi:10.1161/CIRCULATIONAHA.113.002283. PMID 23935011
  81. Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335–346. doi:10.1056/NEJMoa1806311. PMID 30625070
  82. Sekela ME, Snyder EL, Welsby IJ, et al. Transfusion of amustaline/glutathione pathogen-reduced red blood cells in cardiac surgery: a randomized phase 3 clinical trial. Anesthesiology. 2025;143(5):1196–1210. doi:10.1097/ALN.0000000000005716. PMID 41085306
  83. Shander A, Hardy JF, Ozawa S, et al. A global definition of patient blood management. Anesth Analg. 2022;135(3):476–488. doi:10.1213/ANE.0000000000005873. PMID 35147598
  84. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362(7):600–613. doi:10.1056/NEJMoa0904084. PMID 20164484
  85. Society for Maternal-Fetal Medicine (SMFM); Mari G, Norton ME, et al. Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #8: the fetus at risk for anemia—diagnosis and management. Am J Obstet Gynecol. 2015;212(6):697–710. doi:10.1016/j.ajog.2015.01.059. PMID 25824811
  86. Sperry JL, Guyette FX, Brown JB, et al. Prehospital plasma during air medical transport in trauma patients at risk for hemorrhagic shock. N Engl J Med. 2018;379(4):315–326. doi:10.1056/NEJMoa1802345. PMID 30044935
  87. Sperry JL, Guyette FX, Rosario-Rivera BL, et al. Early cold stored platelet transfusion following severe injury: a randomized clinical trial. Ann Surg. 2024;280(2):212–221. doi:10.1097/SLA.0000000000006317. PMID 38708880
  88. Stanworth SJ, Estcourt LJ, Powter G, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med. 2013;368(19):1771–1780. doi:10.1056/NEJMoa1212772. PMID 23656642
  89. Steele WR, Dodd RY, Notari EP, et al. HIV, HCV, and HBV incidence and residual risk in US blood donors before and after implementation of the 12-month deferral policy for men who have sex with men. Transfusion. 2021;61(3):839–850. doi:10.1111/trf.16250. PMID 33460470
  90. Steiner ME, Ness PM, Assmann SF, et al. Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med. 2015;372(15):1419–1429. doi:10.1056/NEJMoa1414219. PMID 25853746
  91. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother. 1996;5(3):213–226. doi:10.1089/scd.1.1996.5.213. PMID 8817388
  92. Toora E, Kulkarni RG, Manivannan P, et al. Quality assessment of platelet concentrates prepared by platelet-rich plasma, buffy-coat, and apheresis methods in a tertiary care hospital in South India: a cross-sectional study. Asian J Transfus Sci. 2023;17(2):239–245. doi:10.4103/ajts.ajts_73_22. PMID 38274963
  93. Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997;337(26):1861–1869. doi:10.1056/NEJM199712253372601. PMID 9417523
  94. US Food and Drug Administration. Alternative Procedures for the Manufacture of Cold-Stored Platelets Intended for the Treatment of Active Bleeding when Conventional Platelets Are Not Available or Their Use Is Not Practical; Guidance for Industry. June 2023. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/alternative-procedures-manufacture-cold-stored-platelets-intended-treatment-active-bleeding-when
  95. US Food and Drug Administration. Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion; Guidance for Industry. September 2019, updated December 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bacterial-risk-control-strategies-blood-collection-establishments-and-transfusion-services-enhance
  96. US Food and Drug Administration. Information for Blood Establishments Regarding FDA's Determination that Zika Virus is no Longer a Relevant Transfusion-Transmitted Infection, and Withdrawal of Guidance. May 12, 2021. https://www.fda.gov/vaccines-blood-biologics/blood-blood-products/information-blood-establishments-regarding-fdas-determination-zika-virus-no-longer-relevant
  97. US Food and Drug Administration. Manufacture of Blood Components Using a Pathogen Reduction Device in Blood Establishments: Questions and Answers; Guidance for Industry. November 2021. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/manufacture-blood-components-using-pathogen-reduction-device-blood-establishments-questions-and
  98. US Food and Drug Administration. Pre-Storage Leukocyte Reduction of Whole Blood and Blood Components Intended for Transfusion; Guidance for Industry. September 2012. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pre-storage-leukocyte-reduction-whole-blood-and-blood-components-intended-transfusion
  99. US Food and Drug Administration. Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Guidance for Industry. May 2023. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-evaluating-donor-eligibility-using-individual-risk-based-questions-reduce-risk-human
  100. US Food and Drug Administration. Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis; Guidance for Industry. May 2019. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-reducing-risk-transfusion-transmitted-babesiosis
  101. US Food and Drug Administration. Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method; Guidance for Industry. September 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-development-blood-collection-processing-and-storage-systems-manufacture-blood
  102. US Food and Drug Administration. Recommendations Regarding License Amendments and Procedures for Gamma Irradiation of Blood Products. Memorandum, July 22, 1993. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-regarding-license-amendments-and-procedures-gamma-irradiation-blood-products
  103. US Food and Drug Administration. Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components; Guidance for Industry. May 2022. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-reduce-possible-risk-transmission-creutzfeldt-jakob-disease-and-variant-creutzfeldt
  104. US Food and Drug Administration. Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria; Guidance for Industry. December 2022. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-reduce-risk-transfusion-transmitted-malaria
  105. US Food and Drug Administration. Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Blood and Blood Components; Guidance for Industry. December 2017. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-serological-tests-reduce-risk-transmission-trypanosoma-cruzi-infection-blood-and-blood
  106. US Food and Drug Administration. 21 CFR 1271.10, Are my HCT/P's regulated solely under section 361 of the PHS Act and the regulations in this part, and if so what must I do? Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271/subpart-A/section-1271.10
  107. US Food and Drug Administration. 21 CFR 1271.3, How does FDA define important terms in this part? Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271/subpart-A/section-1271.3
  108. US Food and Drug Administration. 21 CFR 1271.80, What are the general requirements for donor testing? Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271/subpart-C/section-1271.80
  109. US Food and Drug Administration. 21 CFR 600.15, Temperatures during shipment. Electronic Code of Federal Regulations, accessed November 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-600/subpart-B/section-600.15
  110. US Food and Drug Administration. 21 CFR 606.145 and 606.170, Control of bacterial contamination of platelets; adverse reaction file. Electronic Code of Federal Regulations, accessed November 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-606
  111. US Food and Drug Administration. 21 CFR 606.145, Control of bacterial contamination of platelets. Electronic Code of Federal Regulations, accessed November 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-606
  112. US Food and Drug Administration. 21 CFR 610.40, 610.41, 610.46 and 610.47, Testing requirements, donor deferral and lookback. Electronic Code of Federal Regulations, accessed November 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-610/subpart-E
  113. US Food and Drug Administration. 21 CFR 610.53, Dating periods for Whole Blood and blood components. Electronic Code of Federal Regulations, accessed November 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-610/subpart-F/section-610.53
  114. US Food and Drug Administration. 21 CFR 640.5, 640.21 and 640.65. Electronic Code of Federal Regulations, accessed November 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-640
  115. US Food and Drug Administration. 21 CFR Part 630, Requirements for blood and blood components intended for transfusion or for further manufacturing use (§§ 630.3, 630.5, 630.10, 630.15, 630.20, 630.30, 630.35, 630.40). Electronic Code of Federal Regulations, accessed November 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-630
  116. US Food and Drug Administration. 21 CFR Part 640, Additional standards for human blood and blood products (§§ 640.4, 640.11, 640.24, 640.25, 640.34, 640.54, 640.56). Electronic Code of Federal Regulations, accessed November 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-640
  117. US Food and Drug Administration. BLA approval letter, Procleix Plasmodium Assay, STN BL 125862/0. March 16, 2026. https://www.fda.gov/media/191604/download
  118. US Food and Drug Administration. De Novo classification request for the HEMANEXT ONE system, decision summary DEN BR220665. September 15, 2023. https://www.fda.gov/media/172729/download
  119. US Food and Drug Administration. Requirements for blood and blood components intended for transfusion or for further manufacturing use; final rule. 80 FR 29842 (Part 630 at 80 FR 29898). May 22, 2015; effective May 23, 2016. FR Doc. 2015-12228. https://www.federalregister.gov/d/2015-12228
  120. US Food and Drug Administration. Revisions to the requirements applicable to blood, blood components, and Source Plasma; direct final rule. 72 FR 45883. August 16, 2007. https://www.govinfo.gov/link/fr/72/45883. Confirmation of effective date (February 19, 2008) and technical amendment, 73 FR 7464. February 8, 2008. https://www.govinfo.gov/link/fr/73/7464
  121. Valentini B, Ramirez Zegarra R, Ghi T, Dall'Asta A. Red blood cell alloimmunization and pregnancy: diagnosis and management. Pregnancy (Hoboken). 2025;1(5):e70085. doi:10.1002/pmf2.70085. PMID 42597218
  122. van Baarle FLF, van de Weerdt EK, van der Velden WJFM, et al. Platelet transfusion before CVC placement in patients with thrombocytopenia. N Engl J Med. 2023;388(21):1956–1965. doi:10.1056/NEJMoa2214322. PMID 37224197
  123. Vassallo RR, Murphy S. A critical comparison of platelet preparation methods. Curr Opin Hematol. 2006;13(5):323–330. doi:10.1097/01.moh.0000239703.40297.a5. PMID 16888436
  124. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013;368(1):11–21. doi:10.1056/NEJMoa1211801. PMID 23281973
  125. Warner D, Duncan H, Gudsoorkar P, et al. Indications and complications associated with centrifuge-based therapeutic plasma exchange—a retrospective review. BMC Nephrol. 2025;26(1):87. doi:10.1186/s12882-025-03970-2. PMID 39972423
  126. Wikkelsø A, Wetterslev J, Møller AM, Afshari A. Thromboelastography (TEG) or rotational thromboelastometry (ROTEM) to monitor haemostatic treatment in bleeding patients: a systematic review with meta-analysis and trial sequential analysis. Anaesthesia. 2017;72(4):519–531. doi:10.1111/anae.13765. PMID 28052313
  127. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105–2116. doi:10.1016/S0140-6736(17)30638-4. PMID 28456509
  128. Wong AJ, Paulson RJ. RhD immune globulin administration after early pregnancy loss following fertility treatment: time for national guidelines. F S Rep. 2025;6(4):409–410. doi:10.1016/j.xfre.2025.11.002. PMID 41473571
  129. Yazer MH, Clayton S, Leeper CM, Spinella PC. Survey of quality control testing practices on low titer group O whole blood in the United States. Transfusion. 2026;66(Suppl 1):S82–S86. doi:10.1111/trf.70074. PMID 41518010
  130. Yazer MH, Spinella PC, Anto V, Dunbar NM. Survey of group A plasma and low-titer group O whole blood use in trauma resuscitation at adult civilian level 1 trauma centers in the US. Transfusion. 2021;61(6):1757–1763. doi:10.1111/trf.16394. PMID 33797100
  131. Yoshida T, Prudent M, D'Alessandro A. Red blood cell storage lesion: causes and potential clinical consequences. Blood Transfus. 2019;17(1):27–52. doi:10.2450/2019.0217-18. PMID 30653459
  132. Young P, Crowder L, Steele W, et al. Frequency of rare, serious donor reactions: international perspective. Transfusion. 2021;61(6):1780–1788. doi:10.1111/trf.16333. PMID 33665853
  133. Zantek ND, Alquist CR, Hofmann JC, et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Writing Committee of the American Society for Apheresis: the tenth special issue. J Clin Apher. 2026;41(Suppl 2):e70141. doi:10.1002/jca.70141. PMID 42747330
  134. Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2486–2495. doi:10.1111/jth.15006. PMID 32914582
  135. Zrimsek M, Gubensek J. Coagulation assessment and fibrinogen thresholds in therapeutic plasma exchange—a narrative review. Biomolecules. 2026;16(9):1304. doi:10.3390/biom16091304. PMID 42793136